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“Drug dependence” and the more traditional term “drug addiction” describes 
the human condition in which drug use becomes compulsive, often with 
serious adverse consequences. It concerns a state of psychological, as well 
as physical, dependence. Drug dependence can be viewed as a reversible 
pharmacological situation, whereas addiction describes a chronic, 
reoccurring disorder in which obsessive drug seeking and taking behavior 
persists despite negative consequences (Cami and Farre, 2003). 
In the year 2002, it was estimated that 2 billion people use alcohol, 1.3 
billion people smoke tobacco cigarettes (WHO, 2002), and 185 million 
people use illicit drugs (UNDCP, 2002). There are many different types of 
illicit drugs of abuse, and regional differences exists in the use of the most 
popular ones. 
Addictive substrates are able to relief distress and induce euphoria. The 
brain is able to adapt to the frequent use of these compounds and the 
induced changes in central nervous system will lead to tolerance, physical 
dependence, sensitization, craving, and relapse (Cami and Farre, 2003).  
 
On the basis of learning and memory studies, theories of addiction have 
been developed. These theories overlap in some parts but are not all in 
consensus with each other. Generally, addictive drugs can induce two 
actions, either they act as positive reinforcers, resulting in euphoria, or they 
act as negative reinforcers, alleviating withdrawal symptoms of or dysphoria 
(see figure 1). When addicted, an environmental stimuli associated with 
previous drug use, can induce rewardive feelings or feelings of withdrawal 
or craving even in the absence of the drug (Spanagel and Weiss, 1999; 
Stolerman, 1992). Where reward is immediate, brief (hours) and decreases 
with repetition, the state of withdrawal is delayed, long-lasting (days), and 




Figure 1: the psychological factors involved in development and 
maintenance of addiction (adjusted version of Rang and Dale’s 




Pharmacological characteristics of drugs are important factors determining 
the way drugs are consumed. The lipophilicity of a drug determines the 
speed at which the drug passes the blood-brain barrier, whereas hydrophilic 
properties facilitate the administration of the drug (Farre and Cami, 1991). 
Furthermore, volatile drugs are prone to be inhaled, and heat resistant drugs 
are often smoked, like cannabis and tobacco. Other important characteristics 
of a drug making it highly addictive are the rapid onset and the intensity of 
the effect (Roset et al., 2001). Therefore even between different 
formulations of the same drug, there are differences in the addictiveness 
determined by the speed by which the compound reaches the brain (e.g., 
smoking “crack” cocaine is preferred to intranasal administration) 
(Hatsukami and Fischman, 1996). Compounds having a short half-life, like 
heroine, also produce more abrupt and intense syndromes of withdrawal, 
compared to methadone that has a long half-life (Farre and Cami, 1991). 
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The likelihood of developing addiction is not only depending on the 
consumption of the drug, but personality and psychiatric state together with 
genetic and environmental factors play an equal role. Personality traits, like 
risk-taking and novelty seeking, and mental disorders are major 
conditioning factors in developing drug addiction (Cami and Farre, 2003; 
Helmus et al., 2001). Mental disorders, like schizophrenia, attention-deficit-
hyperactivity-disorder, bipolar disorder, and depression are associated with 
a higher risk of developing addiction. When diagnosed for both a mental 
disorder and substance abuse, the success rate of treatment is usually low 
(Kavanagh et al., 2002).  
Genetic factors may also contribute to the risk of addiction by influencing 
metabolism and the pharmacological effect of drugs (Crabbe, 2001). When 
both parents are alcoholic the child has a higher chance of developing 
alcoholism at a later age (Schuckit and Smith, 2001). With regard to 
nicotine addiction, people who have a mutation in the allele coding for the 
nicotine degradation enzyme, are less likely to develop dependency when 
compared to people who are homozygous for this alleles (Rao et al., 2000). 
Furthermore, when the endocannabinoid system (likely involved in drug 
reward processes) is affected by a single-nucleotide polymorphism in the 
gene coding for fatty-acid-amide-hydrolase (FAAH: endocannabinoid 
inactivating enzyme) there is an increased likelihood of using illicit drugs 
(Sipe et al., 2002). 
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Neurobiological basis of reward 
 
Despite the large differences in the working mechanisms of drugs of abuse, 
each binding to a distinct target protein in the brain which elicits a unique 
combination of behavioral and psychological effects, they share certain 
effects after both acute and chronical administration (Nestler, 2005). 
Virtually all drugs of abuse, including nicotine, cannabinoids, and 
amphetamines, activate the mesocorticolimbic dopaminergic pathway, also 
known as the reward pathway (Carboni et al., 1989; Di Chiara and Imperato, 
1988; Imperato and Di Chiara, 1986; Imperato et al., 1986; Wise and 
Bozarth, 1987). The reward pathway plays a major role in the motivational 
system regulating the responses to natural rewardive processes, such as 
eating, drinking, having sex and social interaction. Drugs of abuse probably 
affect the reward pathway more intensely and with more persistence 
compared to the natural reinforcers. The interaction of drugs of abuse and 
the reward pathway might therefore induce alterations in the reinforcing 
mechanisms. The most important alterations in reinforcing mechanisms are 
tolerance, dependence, and sensitization. Tolerance might be a contributor 
for the intensification of drug intake seen during the development of an 
addiction. Where dependence contributes to the high rates of relapse in the 
early phases of withdrawal, sensitization plays an important role in an 
increased risk of relapse after longer withdrawal periods. 
The cell bodies of the reward pathway originate in the ventral tegmental 
area (VTA) of the midbrain (A10 cell group in rats), and run via the medial 
forebrain bundle to the nucleus accumbens (NAc), prefrontal cortex (PFC), 
amygdala (AMG)  and limbic region (Koob and Nestler, 1997) (figure 2). 
Figure 2 gives a schematic view of the reward pathway with its most 
important connections and involved neurotransmitter systems. Although the 
VTA-NAc connection (especially the NAc shell region) is regarded as the 
most important and is therefore the subject of most studies investigating 
reward processes, other brain-structures like the ventral pallidum (VP), 
medial dorsal thalamus (MDT), hippocampus, PFC, and AMG also seem to 





Figure 2: Schematic view of the reward circuitry and the neurotransmitter systems 
involved. DA neurons cell bodies are localized in the VTA project to the NAc and mPFC 
via the medial forebrain bundle.  In addition  connection to neurons in the hippocampus, 
AMG, VP are described. An inhibitory input via GABA neurons is present from the NAc to 
the VP and to the VTA (possibly as a negative feedback). The NAc is receiving stimulatory 
input via glutamate neurons from the mPFC, hippocampus and AMG. The MDT is 
connected via glutamate neurons to the mPFC. The VTA is known to have glutamatergic 
interneurons that stimulate the DA signals to the NAc.  
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The VTA-NAC connection and reward 
 
It is well recognized that drugs of abuse activate a common circuitry in the 
brain’s limbic system (Di Chiara et al., 2004; Nestler, 2001). Most attention 
has been given to the reward circuitry and within this to the dopaminergic 
projection from the VTA to the NAc. This VTA-NAc connection is 
regarded as being the primary substrate for the acute rewarding effects of all 
drugs of abuse.  
 
The NAc can be divided into two different functional parts: the NAc core 
and NAc shell region. Both these regions of the NAc are implicated in 
processes related to reward and addiction (Bassareo et al., 2002; Di Chiara, 
2002). The NAc shell and core seem to differ in the amount of sensitization 
to drugs (Cadoni and Di Chiara, 1999; Cadoni et al., 2000), their response to 
natural rewardive stimuli like food (Bassareo and Di Chiara, 1999) and their 
reaction in DA release to systemic drug administrations (Di Chiara, 2002). 
Overall the NAc shell seems to be involved in the initial reward processes 
(e.g. the “tasting” part of eating), while the NAc core is involved in the 
reward following the intake of the food (e.g. the feeling of satiety).  
While the DA increase in the NAc is the hallmark of reward, the DA cell 
bodies in the VTA seems to be fundamental in regulating the reward 
processes, and this nucleus is recognized as being the brain area initiating 
most rewardive processes. As a testament to the essential role of the VTA in 
reward it has been shown that the self-administration of nicotine by rats is 
inhibited by local administration of a nicotine-antagonist (dihydro-β-
erythroidine) into the VTA. Furthermore, studies using nicotine 
acetylcholine receptor blockers or knock-outs in the VTA have shown the 
essential role of these receptors within this brain area for nicotine induced 
reward processes both neurochemically and behaviorally (Laviolette and 
van der Kooy, 2003; Maskos et al., 2005; Panagis et al., 2000; Picciotto et 
al., 1998; Pons et al., 2008; Walters et al., 2006). Additionally, it was shown 
that intra VTA infusions of heroin induces conditioned place preference 
(CPP) (Walker and Ettenberg, 2005), and that CPP induced by cocaine was 
completely inhibited by pre-treating the animals with local VTA 
microinjections of a glutamate antagonist (Harris and Aston-Jones, 2003). 
Taken together, these data suggest a crucial role of the VTA in regulating 
drug induced effects and hence mediating addiction. Apart from the DA 
neurons, within the VTA are at least two more neuronal pathways involved 
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in reward (Cameron et al., 1997). One of these are GABAergic neurons, 
which project to the NAc (Van Bockstaele and Pickel, 1995) and PFC (Carr 
and Sesack, 2000), and locally synapse on the VTA DA neurons (Johnson 
and North, 1992; Steffensen et al., 1998). The other neuronal type projecting 
to the VTA is glutamatergic, which are originating from a wide range of 
neuronal substrates (mPFC, AMG, pedunculopontine nucleus and the 
subthalamic nucleus). 
 
Other brain areas involved in reward 
Recent studies have shown that other brain areas are also involved in 
reward, like the AMG, MDT, VP, hippocampus, and (m)PFC (Kalivas, 
2004; Koob and Le Moal, 2001; Nestler, 2001; Robinson and Berridge, 
2003; Volkow et al., 2004). Some of these areas are essential parts of the 
brain’s memory systems, leading to the now confirmed hypothesis that 
important reward processes engage emotional memories (Hyman and 
Malenka, 2001; Kalivas, 2004; Nestler, 2001, 2005; Wise, 2004). 
 
In CPP environmental stimuli are coupled to a primary reward (e.g. sucrose 
of a drug). Since the stimulus then predicts reward for the animal, the animal 
will therefore prefer the environment that is coupled to this rewardive 
stimulus. When bilateral lesions are induced in the basolateral AMG, using 
excitotoxic amino acids, the expression of CPP is abolished (Everitt et al., 
1991). The same study showed that when the DA connection between the 
AMG and the VTA was lesioned CPP was again abolished, suggesting an 
important connection between the AMG and VTA for this behaviour. 
Additionally, in primates by applying aspiration lesions (in which the whole 
AMG is removed) severe impairments in stimulus-reward learning were 
observed (Murray and Mishkin, 1984, 1985; Spiegler and Mishkin, 1981). 
These studies indicate the importance of the AMG in remembering the 
features of rewardive stimuli. 
The role of the MDT in stimulus reward was studied in primates, where 
lesions of the MDT resulted in comparable effects to those observed after 
AMG lesioning (Gaffan and Murray, 1990). Although the AMG is known to 
have interactions with the NAc (Groenewegen, 1988; Kelley et al., 1982), 
no functional connections were identified between the AMG and MDT 
(Gaffan and Murray, 1990). Furthermore, lesions in the MDT completely 
prevented acquisition of place preference, while lesions in the VP only 
attenuated this behavior (McAlonan et al., 1993). While lesions, in both the 
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MDT and VP, did affect the CPP they did not affect the consumption rate of 
the sucrose (the rewardive stimulus). This suggests that both the MDT and 
VP are more involved in the cognitive processes regulating reward and 
addiction, and have no influence on the direct reward (“liking” (Berridge, 
1996)). By contrast, inducing a lesion in the VP pre-conditioning the animal 
in the CPP paradigm, did show a complete absence of place preference, 
while lesioning post-conditioning was ineffective (Hiroi and White, 1993). 
This finding does suggest that the VP is involved in the cognitive processes 
that result in addictive behavior.  
Another brain area that, like the AMG, is implicated in the cognitive reward 
processes is the hippocampus. There are indications that both the 
amygdalar- and the hippocampal-pathways are essential for cue-induced 
drug-seeking/taking (See, 2005). More specifically, the hippocampus is 
thought to be implicated in drug seeking and taking that is elicited by 
contextual (environmental) stimuli, which is confirmed by lesions in the 
hippocampus have shown to prevent the contextual reinstatement (relapse) 
of cocaine administration (Fuchs et al., 2005). 
The mPFC is another brain area believed to be important for the cognitive 
aspects of reward processes ultimately leading to the development or 
reinstatement of addiction. Furthermore, the mPFC is an important brain 
area in regulating impulsive behavior (Pattij and Vanderschuren, 2008), a 
form of behavior that plays an important role in the reinstatement of 
addiction (Fuchs et al., 2004). Neurochemically the mPFC receives 
dopaminergic input from the VTA, as does the NAc shell (Koob and 
Nestler, 1997), and shows a reduction in DA activity during amphetamine 
self-administration, controversially the NAc there is actually an increase in 
DA activity (Piazza et al., 1991). There are glutamatergic projections from 
the mPFC to the NAc which have shown to be involved in the reinstatement 
of cocaine-seeking (McFarland et al., 2003), which further emphasizes the 




Drugs of abuse 
 
Although there are a large number of drugs of abuse, like emphasized 
above, this thesis will focus on nicotine, amphetamine and cannabis, while 
comparisons with other drugs will be made when relevant. 
 
Nicotine 
Like other addictive substrates nicotine induces pleasure and reduces stress 
and anxiety. Nicotine addicts smoke tobacco to modulate levels of arousal 
and to control their mood (Benowitz, 2010). Even though nicotine improves 
concentration, and reaction time, and therefore is regarded as a stimulant, 
this is not the main reason that people keep on consuming cigarettes. Relief 
from withdrawal symptoms is also a strong motivator for smoking of 
cigarettes.  
Amongst the mentally ill, patients with schizophrenia show the highest 
smoking prevalence of about 70-80%, whereas it is 20-30% in the general 
population (Winterer, 2010). Patients with schizophrenia frequently suffer 
from negative symptoms (e.g. avolition, social withdrawal, anhedonia) and 
cognitive deficits, like impaired working memory and attention deficits 
(Gold and Harvey, 1993). Trying to explain the high smoking prevalence 
amongst these patients researchers came up with the self-medication 
hypothesis. This hypotheses states that patients with schizophrenia may 
consume nicotine to self medicate negative symptoms (reviewed by 
(Winterer, 2010). Whatever the reason is that these patients show such a 
high smoking prevalence, it may be concluded that these patients show a 
higher need for nicotinergic stimulation. Therefore, there are currently 
intensive efforts to develop a novel group of drugs targeting the nicotinergic 




Pharmacology of Nicotine 
As a testament for the addictive potential of nicotine it was shown that 
animals can be trained to push a lever to self-administer nicotine (Corrigall, 
1999). Furthermore, cessation of regular nicotine administrations induces 
physical withdrawal signs and symptoms in this animal model of smoking 
addiction. These effects of nicotine are probably regulated mainly by 
nicotinic acetylcholine receptors, present in the brain.  
 
 
Nicotinic Acetylcholine Receptors 
Acetylcholine is an important excitatory neurotransmitter in the central 
nervous system (CNS). The effects of acetylcholine are mediated by two 
receptor types, the muscarinic and the nicotinic. There are five subtypes of 
the G-protein coupled muscarinic receptors (M1 to M5) of which the neural 
subtypes mediate processes like, for instance, memory. The nicotinic 
acetylcholine receptors (nAChR’s), known from the neuromuscular junction 
in ganglia are involved in fast excitatory transmission in the brain. 
All nAChR’s are, like GABAA, glycine, and 5-HT3, members of the ligand-
gated ion channel family (Akabas and Karlin, 1995; McGehee and Role, 
1995). These nicotinic receptors consist of a pentameric cylindrical structure 
organized around a central pore which is permeable to Na+, K+, and Ca2+ 
(Cooper et al., 1991). Cloning the nAChR’s gave eight possible neuronal 
subunits of which the pentameric cylindrical structure is designed (α2 - α7 
and β2 - β4) (Chini et al., 1994; Elgoyhen et al., 2001; Lukas et al., 1999). 
Neuronal nAChR’s are composed of a combination of α- and β-subunits. 
The numbers of available nAChR subunits facilitate a large amount of 
possible receptor subtypes. Moreover, a single neuron may express more 
than one nAChR subtype, with each subtype serving a different function. 
Therefore making a prediction of the distribution of nAChR subtypes, based 
on the gene expression of each subunit, is not an easy task. From in situ 
hybridization and immunohistochemical studies it has become clear that the 
subunits α4, β2, and α7 are the most abundantly expressed in the mammalian 
brain (Hill et al., 1993; Marks et al., 1992; Seguela et al., 1993; Wada et al., 
1989). Although there is partly overlap of expression, each α-subunit has a 
unique set of neuronal structures (Wada et al., 1989). Of all α-subunits, α4 is 
the most abundant in the brain and together with the β2 subunit accounts for 
more than 90% of nicotine binding sites in the rat brain (Flores et al., 1992; 
Wada et al., 1989; Whiting and Lindstrom, 1986). Like the α4 the α7- 
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subunit is distributed throughout the brain with dense populations in the 
cortical and limbic areas (Orr-Urtreger et al., 1997). In contrast, the α2, α3, 
and α5 are only found in limited areas of the mammalian brain (Lena and 
Changeux, 1997; Wada et al., 1990). 
From the β-subunits, β2 is the most abundant and its mRNA is widely 
expressed, together but not exclusively, with the α4 mRNA (Hill et al., 1993; 
Lena and Changeux, 1997). Their distribution parallels the location of high-
affinity nicotine binding sites in the brain, like in the thalamus, striatum and 
cortex (Clarke et al., 1985). 
 
Like all ligand-gated ion channels, opening of the nAChR receptor channel 
requires the binding of a ligand, like nicotine. When the ligand is bound to 
the receptor-site all subunits will undergo a conformational change opening 
a pore and allowing ions (Na+, K+) to flow in or out of the cell eventually 
leading to depolarization of the neuron. 
 
Nicotine and dopamine 
When nicotine reaches the brain it binds and activates nAChRs throughout 
the whole brain (Clarke et al., 1985). Within the reward circuitry nicotine is 
believed to bind both the nAChRs in the VTA (Maskos et al., 2005; 
Picciotto, 1998; Pons et al., 2008; Walters et al., 2006) and NAc shell region 
(Clarke et al., 1985; Harfstrand et al., 1988; Kamiya et al., 1982; Mifsud et 
al., 1989). Upon stimulation of the nAChRs the DA neuron in the VTA is 
stimulated directly or indirectly by activating nAChRs located on either 
glutamate or GABA neurons within the VTA. The result of this stimulatory 
effect in an increase in NAc shell DA release. However, within the NAc 
shell itself there are also nAChRs located that, upon activation by binding 
with nicotine, could directly stimulate local DA release from DA terminals. 
The fact that nicotine is binding at both sides of the reward circuitry makes 
it difficult to understand the exact neurochemical processes that determines 
the rewardive effect of nicotine. Since there are different types of receptors 
(α7, α4β2) localized in the VTA and NAc the key of nicotine reward is 
probably activation of a unique combination of these receptor types. 
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Amphetamine 
Amphetamine like drugs and stimulants such as amphetamine, 
dextroamphetamine, but also methylphenidate (Ritalin) are known to have 
both central and peripheral effects. The main central effects are an increase 
in locomotor activity, euphoria, excitement, and stereotyped behavior. 
Amphetamines are also known to have a strong anorexic effect and have 
been used for weight loss. In the periphery amphetamine increases blood 
pressure and inhibits gastrointestinal motility.  
Amphetamine is also used by students to improve performance during 
exams. The compound has indeed been shown to increase cognitive tasks in 
humans (Barch and Carter, 2005). 
During repeated use within a short time-frame, amphetamine might induced 
a state of psychosis (Shoptaw et al., 2009), closely resembling an acute 
schizophrenic attack (hallucinations, paranoia, and aggressive behavior).  
When the effect of amphetamine wears down, there is usually a period of 
deep sleep from exhaustion, followed by feelings of lethargy, depression, 
anxiety and hunger (Zorick et al., 2010). These effects might be the result of 
depletion of catecholamine stores. Dependence on amphetamine appears to 
be the result of these unpleasant withdrawal effects and the memory of 
euphoria, which will motivate the user to administer another dose. Repeated 
amphetamine use will rapidly develop tolerance, especially the peripheral 
sympathomimetic and anorexic effects, but more slowly to the other effects 
(locomotor and stereotypics) (Wolgin, 2000). 
 
 
Amphetamine-like drugs as medicine 
Amphetamine has the characteristics of a highly addictive drug of abuse. 
The effect of amphetamine is fast, pleasurable and when it wears down 
leaves withdrawal feelings which motivate the following administration. 
Indeed, amphetamine has shown to be self-administered by rats trained to 
push a lever to receive an administration of the drug (Lyness et al., 1979).  
Furthermore, because of its importance in a range of psychiatric disorders, 
including personality disorders, drug addiction, and attention-
deficit/hyperactive-disorder (ADHD), impulsive behavior has received a 
great deal of attention in scientific studies. Amphetamine is a often used 
model for studying the impulsive decision making in animal models (Pattij 
and Vanderschuren, 2008; van Gaalen et al., 2006). 
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In this regard it is of interest to note that amphetamine-like drugs are 
frequently prescribed as medicine for ADHD. Since a major physical effect 
of amphetamine is hyperactivity, it seems paradoxically that amphetamines 
are the medicine of choice in the treatment of ADHD. Methylphenidate 
(Ritalin) is commonly used to treat ADHD at doses lower than those causing 
euphoria and other side-effects. ADHD is a common condition in children in 
which the over-activity and lack of attention-span disturbs their social 
development and educational performance. In this group of subjects 
amphetamines are regarded as a safe and effective drug. Despite of the 
effectiveness and safety of these drugs, which is confirmed by controlled 
clinical trials (e.g. (Greenhill et al., 2006; Wigal et al., 2004), the clinical 
usefulness is limited by the risks of adverse effects (hypertension, insomnia, 
anorexia, tremors, and the risk of dependence). 
 
 
Amphetamine and dopamine 
Amphetamines are known to increase the extracellular levels of dopamine 
and noradrenaline (NE) in the brain. As dopamine is the crucial transmitter 
in the reward circuitry, the characteristic behavioural effects of 
amphetamine are very likely explained by this pharmacological effect. This 
hypothesis is supported by the observation that the stereotyped behavioral 
effects of amphetamines are absent after depleting the brain from DA with 
the specific neurotoxin 6-hydroxydopamine or by preventing the 
catecholamine  syntheses by pretreatment with α-methyltyrosine (Gold et 
al., 1989; Jones et al., 1989).  
There are multiple ways by which amphetamine can increase catecholamine 
levels in the synaptic cleft, First, amphetamine binds to the pre-synaptic 
membrane of DA neurons and induces the release of DA from its terminals. 
Second, amphetamine can bind and inhibit the monoamine degradation 
enzyme monoamine oxidase in the DA neurons. Third, amphetamine can 
stimulate DA containing vesicles to release DA into the synaptic cleft, and 
fourth, amphetamine is able to prevent DA re-uptake by binding and 
blocking the DA re-uptake transporter.  
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Cannabis 
Although cannabis/marijuana is prescribed for medication purposes (pain 
relief, treatment of nausea or premenstrual syndrome) for centuries, the use 
of marijuana for recreational purposes has always accompanied its medical 
benefits. Marijuana or hashish induces the feeling of relaxation and well-
being while it impairs cognitive processes. However, an overdose of 
cannabis can induce panic attacks and even psychotic episodes (Hall and 
Solowij, 1998). Among patients with schizophrenia or other mental 
disorders there is a relative high incidence of cannabis consumption 
(Zammit et al., 2002). Compared to other drugs of abuse, like ethanol, the 
withdrawal symptoms of cannabis (restlessness, irritability, and insomnia), 
are subtle and are mainly restricted to the heavy users (Budney et al., 2001). 
The long-term effect of repetitive use of high cannabis doses is a subject of 
debate and concern. Although there is evidence for the negative effects of 
cannabis use on memory (Bolla et al., 2002; Solowij et al., 2002), the impact 
of other with cannabis use associated symptoms (like the marijuana 
amotivational syndrome) remain unclear (Hall and Solowij, 1998).  
 
Neurochemistry of Cannabis 
Although the addictive properties of cannabis have been debated during 
many years,, it is now accepted that cannabis is in fact addictive. Cannabis 
has shown to act upon reward processes in a manner which is consistent 
with other drugs of abuse (Lupica et al., 2004). Cannabis induces CPP, 
which is mediated by CB-1 receptors, since its antagonist SR141716A 
reverses the process (Gardner, 2002; Tanda and Goldberg, 2003). In initial 
experiments cannabis was not active in a self-administration paradigm 
(where animals are trained to push a lever, or do a nose poke to receive a 
dose of cannabis) (reviewed by (Tanda and Goldberg, 2003), However after 
careful control of dose and vehicle cannabis robustly induced self-
administration in primates at doses comparable to those observed in 
marijuana smokers (Tanda and Goldberg, 2003; Tanda et al., 2000). 
Consistent with most drugs of abuse, cannabis also showed to lower the 
threshold for intra-cranial self stimulation (ICSS) in the medial forebrain 
bundle (Gardner and Lowinson, 1991),  
 
In the late 1980’s it was suggested that specific CB receptors existed, and 
that the effect of cannabinoids was not just the result of alterations of 
cellular membrane structures (Devane et al., 1988; Howlett et al., 1990). 
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Soon after this suggestion the first CB receptor, the CB-1 receptor, was 
cloned and sequenced (Matsuda et al., 1990). The discovery of this receptor 
was followed shortly by the identification of a second CB receptor, called 
the CB-2 receptor (Munro et al., 1993). The CB-1 receptor is mainly found 
in the CNS whereas the CB-2 receptor is mainly present in lymphoid tissue 
and has an important function in the immune system (Nocerino et al., 2000). 
However, more recently the CB-2 receptor was also found in the brain 
(reviewed by (Atwood and Mackie, 2010) and although the central 
relevance of the CB-2 receptor remains under discussion, they have recently 
been implicated in cocaine induced reward (Xi et al., 2011).  Some studies 
also suggested the existence of an additional non-CB-1 and non-CB-2 
receptor (Begg et al., 2005; Breivogel et al., 2001; Freund and Hajos, 2003; 
Fride et al., 2003; Hajos et al., 2001; Jarai et al., 1999; Ryberg et al., 2007; 
Zimmer et al., 1999) of which the neurological significance needs more 
investigation. Because of its role in mediating neurotransmission in the CNS 
the CB-1 receptor will be the main focus of this thesis. 
 
CB-1 receptors are the most abundant G-protein coupled receptors present 
in the brain (Howlett, 2002). CB-1 receptors are of the metabotropic type 
and coupled to Gi/o proteins whose activation results in an inhibition of 
adenyl cyclase activity. A decrease in adenyl cyclase activity consequently 
results in a decrease in cyclic AMP content in the cytosol. This also closes 
Ca2+ channels, opens of K+ channels, and stimulation of the kinases that 
phosphorylate tyrosine, serine, and threonine (Howlett, 1998; McAllister 
and Glass, 2002). CB-1 receptors are located on the presynaptic nerve 
ending and are therefore believed to inhibit the release of glutamate, GABA, 
serotonine, and other neurotransmitters (Schlicker and Kathmann, 2001; 
Wilson and Nicoll, 2002). 
Stimulation of CB-1 receptors inhibits both the excitatory input of glutamate 
(Melis et al., 2004b; Pistis et al., 2002; Robbe et al., 2001) and the inhibitory 
input of GABAergic neurons (Szabo et al., 2002) within the VTA on DA 
neurons. Regulating the excitatory and the inhibitory input within a system 
projects the CB-1 receptor as an important modulator of (DA) nerve 
activity. 
Additionally, cannabinoids have shown to decrease acetylcholine (ACh) 
release and activity (Carta et al., 1998; Gessa et al., 1998; Gessa et al., 1997; 
Gifford et al., 2000; Narushima et al., 2007). Controversially, also 
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stimulatory effects of cannabinoids on ACh release are shown (Acquas et 
al., 2000; Acquas et al., 2001; Degroot et al., 2006; Verrico et al., 2003).  
Norepinephrine nerve activity is also frequently linked the activity of CB-1 
receptors (Mendiguren and Pineda, 2006; Oropeza et al., 2005; Schlicker et 
al., 1997; Tzavara et al., 2001), while other neurotransmitters are less often 
linked to CB-1 receptor activity, such as histamine and cholecystokinin 
(Beinfeld and Connolly, 2001; Cenni et al., 2006). 
 
The localization of CB-1 receptors in the brain is consistent with the known 
effects of cannabinoids. The highest concentrations of CB-1 receptors are 
found in areas involved in memory (e.g. hippocampus), motor coordination 
(e.g. cerebellum), and emotions (e.g. prefrontal cortex) (Herkenham et al., 
1990; Tsou et al., 1998). These reports also show that in the terminal region 
of the brain reward circuitry average to high CB-1 receptors densities are 
found, while in the VTA only low concentrations of CB-1 receptors were 
reported. The relatively low levels of CB-1 receptors within the VTA do not 
implicate that there is no functional role of CB-1 receptors on processes 
within this region. In fact, several studies have shown that cannabinoids 
directly affect VTA neuron activity (Cheer et al., 2003; Melis et al., 2004a; 
Melis et al., 2004b; Riegel and Lupica, 2004; Szabo et al., 2002), suggesting 
an important role in reward processes (Zangen et al., 2006). 
 
Since the CB-1 receptors are so widely distributed, abundant in high 
numbers, and upon receptor stimulation have an inhibitory effect on 
multiple neurotransmitter systems it seems only logical that the activity of 
this receptor has major influences on both endogenous and exogenous (e.g. 
drug induced/medication) processes. A pronounced and clinically relevant 
interaction of the CB-1 receptor with an SSRI (selective serotonine reuptake 
inhibitor; the most prescribed class of antidepressants) will be described in 




Although investigation of the rewarding effects of cannabis is interesting 
and highly relevant, the focus of this thesis will be the role of 
endocannabinoids (ECs) in the regulation of brain neurotransmitter release 
and activity within the reward circuitry.  
ECs, like anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are 
retrograde messengers which implicate that they are synthesized 
postsynaptically in an activity-dependent manner (on demand), travel the 
synaptic cleft and interact with presynaptic CB-1 receptors on both 
excitatory and inhibitory afferents (Harkany et al., 2008). After binding to 
the CB-1 receptor, their action is inhibition of nerve activity and thus 
decreasing neurotransmitter release. 
In the early 1990s, AEA (Devane et al., 1992; Di Marzo et al., 1994) and 2-
AG (Mechoulam et al., 1995; Stella et al., 1997; Sugiura et al., 1995) were 
discovered as the first endogenous ligands to the CB-1 receptor. Following 
AEA and 2-AG other possible ECs have also been proposed, like 
virodhamine (Porter et al., 2002), noladin ether (Hanus et al., 2001), and 
arachidonoyldopamine (Porter et al., 2002), but their physiological role and 
natural occurrence remains a subject of debate.  
AEA and 2-AG have different structures, are synthesized via different 
pathways, and have different degradation pathways. AEA is degraded by 
fatty-acid-amide-hydrolase (FAAH) into arachidonic acid and ethanolamine, 
whereas 2-AG is mainly degraded by monoacylglycerol lipase (MAGL). 
Furthermore, these ECs appear to be formed under the different conditions 
and to be differently affected by several manipulations, including 
pharmacological stimulation [reviewed by: (Di Marzo et al., 2004; Freund et 
al., 2003; Piomelli, 2003)].  
There are also endocannabinoids that have no affinity for the CB-1 receptor, 
like OEA and PEA. These ECs bind to the nuclear transcription factor 
peroxisome proliferator-activator (PPAR-α) receptor, on which they display 
agonistic actions (Fu et al., 2003). These receptors appear to be generally 
distributed in the CNS (Moreno et al., 2004), and present in the cortex, 
VTA, midbrain, medulla, hippocampus, substantia nigra, and olfactory 
tubercle (Cullingford et al., 1998; Deplanque et al., 2003; Kainu et al., 1994; 
Kreisler et al., 2007; Moreno et al., 2004).  
AEA and 2-AG are believed to be involved in a wide range of processes, 
symptoms, and diseases, like: pain, motor-functions, schizophrenia, 
cognitive functions, sleep, feeding and appetite [reviewed in (Fride, 2002)]. 
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While there is less known about the physiologic role of OEA and PEA, they 
have been implicated to have neuroprotective effects, to modulate DA 
neurons, to increase neurosteroïd production and to play a role in memory 
consolidation, seizure protection, and inhibition of tumor proliferation 
(Campolongo et al., 2009; Mazzola et al., 2009; Melis et al., 2008; Morales 
et al., 2007; Sasso et al., 2010; Sheerin et al., 2004; Sun et al., 2007). 
However, this thesis will mainly focus on the role of ECs in regulating 
reward processes, and their relevance in the development and reinstatement 
of drug addiction. 
AEA and 2-AG can serve as powerful reinforcers of self-administration in 
primates when injected intravenously (Justinova et al., 2005; Justinova et 
al., 2011). Furthermore, when given intravenously AEA increases 
extracellular DA levels in the NAc shell, a neurochemical feature regarded 
as the hallmark of reward (Solinas et al., 2006). Importantly these 
reinforcing effects of AEA are CB-1 mediated, and are potentiated by 
FAAH inhibition, which increases the levels of AEA, OEA and PEA in the 
synaptic cleft (Solinas et al., 2006). In addition, systemic AEA 
administrations was found to increase food intake (Hao et al., 2000), which 
was mimicked by local-infusion of AEA into the NAc (Mahler et al., 2007). 
Whereas AEA appears to stimulate food intake, 2-AG is suggested to be 
more important for appetitive aspects than the consummatory aspects of 
food reward (Kirkham et al., 2002).  
This individuality of each EC in regulating specific reward processes is 
further emphasized by the fact that the extracellular levels of each EC 
respond different to self-administration of drugs of abuse (Caille et al., 
2007). ECs are thought to modulate the rewarding properties of nicotine 
through a CB-1 mechanism (Merritt et al., 2008). Administration of the CB-
1 antagonist rimonabant, decreased nicotine self-administration and CPP in 
rats (Cohen et al., 2005a; Cohen et al., 2005b; Le Foll and Goldberg, 2004), 
confirming an involvement of endocannabinoid signaling in nicotine 
reinforcement. Supporting this notion, CB-1 knock-out mice did not display 
nicotine induced-CPP (Castane et al., 2005; Merritt et al., 2008). 
Furthermore, inhibition of FAAH, by administration of URB597, showed to 
dose-dependently increase the nicotine rewarding properties, measured by 
CPP (Merritt et al., 2008). These results indicate that ECs binding to the 
CB-1 receptor are crucial to nicotine’s rewardive value. 
However, OEA and PEA have also shown to be involved in nicotine 
induced reward processes. More specifically, there is one study that 
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demonstrates their inhibitory role on nicotine induced DA release in 
mesolimbic areas (Melis et al., 2008). These findings introduce the PPAR-α 





Analytical methods for ECs 
To understand the mechanism of action of drugs in vivo monitoring 
techniques of the neurochemistry of the CNS are essential. There are several 
methods for monitoring brain constituents, like neurotransmitters, during or 
after a pharmacological challenges. Tissue constituents can be analyzed 
post-mortem, implicating the possibility for studying multiple analytes 
(depending on the analytical method and sample preparation). However, a 
major disadvantage of this technique is the amount of animals required 
when studying the effects on different points in time. Furthermore, post-
mortem degradation, release or even syntheses of the analyte, like ECs, 
hamper the physiological relevance of these findings (Bazinet et al., 2005; 
Hansen and Diep, 2009; McCue et al., 2009). 
Techniques that display an acceptable time-resolution and are able to 
monitor effects of a stimulus in a specific tissue in a freely moving animal 
are intracerebral electrophysiological recordings or the use of implanted 
biosensors and microdialysis probes. Electrophysiological recording is a 
method that relies on the electrical properties of tissues and cells. It 
implicates recording of the electrical activity of neurons, and particularly 
their action potential activity. While electrophysiology studies detect the 
activity of specific neurons, microdialysis and biosensors monitor the 
extracellular content of neurotransmitters and related compounds. There are 
different types of biosensors used to monitor CNS constituents. For routine 
use commercial available amperometric biosensor are of interest. There are 
two types of biosensors; those using cyclic voltametry [carbon fibers used 
by the group of Wightman (Kita and Wightman, 2008)] and those who are 
based on enzymatic catalysis of a reaction that produces or consumes 
electrons (by redox enzymes). The advantage of the latter is the specificity 
(enzyme dependent) and high time-resolution (sub-second measurements). 
However, disadvantages are the fact that only one analyte is monitored, 
possible interference signals of easily oxidizing compounds (like 
arachidonic-acid), and biofouling. 
Microdialysis represents an I-shaped semi-permeable membrane tube that is 
implanted stereotactically into the brain area of interests. A dialysis buffer, 
closely resembling the ionic composition of the extracellular fluid, perfuses 
the membrane via tubing attached to a syringe pump. Substances in the 
brain, that are small enough to pass through the membrane (e.g. 
neurotransmitters and peptides), will diffuse into the buffer and carried 
through the connective tubing to a collection vial (Parent et al., 2001; 
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Torregrossa and Kalivas, 2008). Depending on the analyte or group of 
analytes, samples can then be analyzed by means of analytical methods such 
as HPLC, LC-MS(/MS), ELISA, etc. An extra dimension is added to the 
microdialysis method when a second probe is implanted (called the dual-
probe method). This approach enables to study interactions between specific 
pathways such as the mesolimbic DA pathway (Westerink et al., 1996). 
Because of its robustness and the possibility of sampling multiple analytes, 
microdialysis is the preferred method in this thesis. 
Because ECs display a high lipophilicity current sample conditions for 
microdialysis result in an unacceptable low recovery. In order to improve 
the recovery of the ECs we have optimized the sampling conditions [see 
chapter 5 and (Buczynski and Parsons, 2010)]. 
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Objectives of this Thesis 
 
This thesis is based on five different studies, each with a unique 
experimental setup. The main objective of this thesis was to critically 
evaluate and further investigate the role of the cannabinoid CB-1 receptor 
and its ligands in the neurochemistry of reward processes that are relevant 
for addiction. 
In Chapter 2 we developed and evaluated the nicotine induced reward 
processes by monitoring extracellular DA in the VTA and the NAc shell). 
The microdialysis technique was used to monitor DA. The efficacy of the 
nicotine-induced release of DA in the two brain areas were compared.  
In Chapter 3 amphetamine was used to increase DA levels in the NAc and 
PFC, both areas are involved in the regulation of impulsivity, a behavioral 
parameter important for reinstatement of addiction. The goal of this study 
was to investigate whether the effect of amphetamine on monoamines such 
as DA, NE and serotonin – determined by the microdialysis method - was 
regulated by CB-1 receptors.  
In Chapter 5 we describe an elaborate the microdialysis method of the ECs: 
AEA, 2AG, OEA, and PEA. Because these compounds display a high 
lipophilicity current sample conditions for microdialysis cannot be used. In 
order to improve the recovery of the ECs we have optimized the sampling 
conditions. One of the critical parameters appeared the recovery of perfusion 
fluid itself. An altered fluid recovery might either drain or perfuse the 
extracellular fluid in the sampled brain region. 
In the final study the role of ECs in the VTA-DA reward circuitry was 
studied during nicotine administration (Chapter 6). In this chapter we used 
the optimal sampling conditions for the ECs (determined in Chapter 5), and 
applied the double probe microdialysis setup and pharmacological treatment 
that was developed in Chapter 2.   
 
Although these were the main focus points of the thesis, no unexpected 
interesting and probably clinically relevant finding would be left 
unevaluated. An example of such observation is presented in chapter 4, 
where we found an interaction between the CB-1 receptor and the efficacy 
of the SSRI citalopram to increase extracellular 5-HT. This interaction 
might have clinical implications for the use of anti-depressives.  
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Nicotine stimulates dopamine (DA) cell firing via a local action at 
somatodendritic sites in the Ventral Tegmental Area (VTA), increasing DA 
release in the Nucleus Accumbens (NAcc). Additionally, nicotine may also 
modulate DA release via a direct effect in the NAcc. This study examined 
the contribution of the latter mechanism on NAcc DA release by applying 
nicotine systemically, as well as locally in the VTA and NAcc shell region 
in rats. Furthermore, the effect of i.v. nicotine on cell firing rate of 
dopaminergic neurons in the VTA was measured. Systemic administration 
of nicotine (0.32mg/kg s.c.) increased extracellular DA levels in the NAcc 
to ~1.5 fold of baseline, while DA levels in the VTA remained unaffected. 
A similar DA increase was observed after local NAcc infusion of nicotine 
(1µM and 10µM). However, 10 to 1000-fold higher nicotine concentrations 
were required in the VTA to produce a comparable 150% increase in 
extracellular DA levels in the ispilateral NAcc. Additionally, 
electrophysiological experiments showed that the dopaminergic firing rate 
in the VTA showed a trend towards an increase after a nicotine dose of 
0.1mg/kg i.v. Taken together these data indicate that the effects of nicotine 
on DA release at the level of the NAcc might be more important for the 








The addictive nature of smoking tobacco is thought to be mainly due to one 
compound: nicotine (Stolerman and Jarvis, 1995). The DA hypothesis of 
drug addiction states that the crucial common reinforcing property of drugs 
of abuse is an increased DA release (Di Chiara and Imperato, 1988; Wise 
and Bozarth, 1987), in the NAcc (Nestler, 2005; Nisell et al., 1994b). 
Nicotine fits this hypothesis as supported by studies where the toxin 6-
hydroxydopamine injected into the rat NAcc blocked nicotine self-
administration (Corrigall et al., 1994).  
Other research showed that nicotine stimulates DA cell firing and 
subsequently increases DA release in the NAcc via local action at 
somatodendritic sites in the VTA (Ikemoto, 2007). These sites are populated 
by nicotinic acetylcholine receptors (nAChRs) and are activated during 
nicotine induced reward (Corrigall et al., 1994; Wolske et al., 1993). Central 
nAChRs consist of variable numbers of α and β receptor subunits. The α7 
and the α4β2 receptor are widely expressed on dopaminergic neurons in both 
the NAcc and VTA (Clarke et al., 1985; Kamiya et al., 1982).  
Convincing results from receptor blockades and nAChR knockout (KO) 
mice have shown that a range of nAChRs (β2, α4, α6, α7) in the VTA are 
crucial for nicotinic reward (Laviolette and van der Kooy, 2003; Panagis et 
al., 2000; Picciotto et al., 1998; Pons et al., 2008). When the nAChR β2-
subunit was knocked-out mice no longer exhibited conditioned place 
preference (CPP) (Walters et al., 2006). After restoring the β2-subunit by a 
VTA lentiviral vector injection, the nicotine-induced DA release and 
electrophysiological response to nicotine were restored (Maskos et al., 
2005). Additionally, the α4 and α6 subunit containing nAChRs within the 
VTA have shown to play a crucial role in the self-administration of nicotine 
(Pons et al., 2008), and the α7 is suggested to be specifically involved in the 
mediation of nicotine induced reward signals (Laviolette and van der Kooy, 
2003). Taken together, these data suggest a crucial role of the nAChRs in 
the VTA in regulating nicotine effects and hence mediating addiction. 
 
However, the nAChRs on DA neurons in the VTA are pharmacologically 
different of those on the nerve terminals in the NAcc, as the sensitivity to 
nicotine, Acetylcholine, and epibatidine were shown to differ in both areas 
(Reuben et al., 2000). Furthermore, nicotine has apart from effects in the 
VTA, also shown to have its primary binding sites in the NAcc, as local 
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infusions of nicotine in the NAcc cause an increase in NAcc DA release 
(Mifsud et al., 1989). It was shown that blocking the α7-nAChRs in the 
NAcc before systemic nicotine prevents the increase in NAcc terminal DA 
(Fu et al., 2000). These direct effects of nicotine in the NAcc suggest a role 
of NAcc nAChRs in mediating accumbal DA responses to nicotine. 
 
Therefore, we investigated the role of the nicotine on dopaminergic neurons 
in both the VTA and the NAcc shell in rats. Nicotine was administered 
systemically, or locally infused into the VTA or NAcc and effects on DA 
release were monitored by microdialysis. Additionally, the effect of i.v. 
nicotine administration on the firing rate of VTA DA neurons was measured 




Materials and Methods 
 
Animals  
Male Sprague-Dawley rats (n=62; 275-320g; Harlan, The Netherlands) were 
used. After surgery, animals were individually housed in plastic cages 
(35x35x40cm) with ad libitum food and water. Experiments were approved 
by the IACUC of the University of Groningen. 
 
Drugs and drug treatment 
Nicotine-di-tartrate was purchased from Sigma-Aldrich (CAS:65-31-6) and 
apomorphine from Research Biochemicals International (CAS:314-19-2). 
Nicotine was dissolved in saline for systemic injections, or in Ringer’s 
solution for infusion by retrograde microdialysis (pH 7). Doses and 
concentrations of nicotine are given as free base. Apomorphine was 
dissolved in 0.5mg/ml ascorbic acid. 
 
Surgery and microdialysis 
I-shaped 9mm long microdialysis probes (1.5mm exposed membrane; 
polyacrylonitril, MWcut-off 40-50kDa; Brainlink, the Netherlands) were 
implanted simultaneously in the NAcc shell (coordinates from bregma and 
dura;Paxinos and Watson, 2007: A/P 2.0, L/M 1.2, V/D -7.9) and the VTA 
(coordinates: A/P -5.0, L/M 0.9, V/D -8.2).  Probes were implanted under 
isoflurane anesthesia (2.5%, 0.6l/min (O2)) and local analgesia with 
bupivacaine and finadyne (2mg/kg, 1ml/kg s.c.) for postoperative analgesia. 
Microdialysis experiments were carried out after a 24-48h recovery period 
by perfusing the probes with Ringer’s solution (in mM: NaCl 140.0, KCl 
4.0, CaCl2 1.2, MgCl2 1.0) at a flow rate of 1.5µl/min (CMA402 syringe-
pump, CMA microdialysis). To study the effect of systemic nicotine, 
microdialysis samples were taken from both the NAcc and the VTA and 
analyzed for DA. To study the effect of local nicotine infusions, retrograde 
dialysis was used to administer nicotine directly into either the NAcc or 
VTA (in separate experiments). In these experiments DA was determined in 
the NAcc only. 20 minute samples were collected using a fraction collector 
(Univentor820 microsampler, TSE systems) and samples were stored at -
80oC until analysis. After the experiment the animal was euthanized using 






DA was quantified by HPLC with electrochemical detection. A Shimadzu 
LC-10-AD pump was used in combination with a C18 column (150x4.7mm2; 
Supelco LC18, USA), connected with an electrochemical detector (ESA 
5011A, potential first cell: 300mV; potential second cell: -300mV). The 
mobile phase consisted of 0.1M sodium acetate adjusted to pH 4.2 with 
acetic acid, 1.8mM octane sulfonic acid, 0.3mM Na2-EDTA, and 120ml/L 
MeOH at a flow rate of 1.0ml/min. The detection limit of the assay was 
~0.05nM DA.  
 
Electrophysiological experiments 
Electrophysiological experiments were carried out similar to Dremencov et 
al. (Dremencov et al., 2009). Additionally the cell type was verified by 
administration of, the DA agonist, apomorphine. Rats were anesthetized 
with chloral hydrate (400mg/kg i.p. additionally 100mg/kg when required). 
Although DA neurons are commonly studied using chloral hydrate, it cannot 
be excluded that the anesthesia influenced the results. 
 
Data analysis 
Microdialysis data were expressed as percentages of baseline DA levels. To 
determine nicotine sensitivity of the NAcc and VTA, the Area Under Curve 
(AUC), based on relative response, during treatment (t=0 to t=260 min) was 
calculated after baseline substraction. For effect of treatment statistical 
analysis was performed with one or two-way analysis of variance for 
repeated measures (ANOVA), followed by Student Newman Keuls post-hoc 
analysis. Electrophysiological data were analyzed by students T-test for 




Systemic nicotine preferentially increases DA release in NAcc shell 
Injections with 0.32 mg/kg s.c. nicotine caused a significant increase in 
extracellular DA in the NAcc shell 20 min after administration to 163 ± 20% 
of basal at t = 40min (F(10,45)=6.642; p < 0.001; n=5; figure 1). From 80 
minutes onward, there was no significant difference in DA levels compared 
to baseline. DA release in the VTA, from the same rat, was not significantly 
affected by nicotine administration (figure 1).  
Basal concentrations (not corrected for recovery) of DA in dialysates, from 
the VTA were (mean ± SEM in pMol / sample) 11.3±1.9 (n=5), and from 
the NAcc shell 53.4 ± 7.9 (n=49). 
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Figure 1: The effect of systemic (s.c.) administration (t=0 min) of 0.32 
mg/kg nicotine on DA release in the NAcc shell (solid circles) and 
VTA (open circles). Data are expressed as percentages of basal levels ± 




The NAcc shell is more sensitive to nicotine infusions, compared to the 
VTA 
When 1µM nicotine was locally infused into the NAcc shell by retrograde 
dialysis, DA release to the NAcc shell increased to 150% of basal levels 
(F(3,290)=4.575; p=0.013; figure 2). Increasing the concentration to 10µM 
produced an increase that was not significantly different from the response 
to 1µM nicotine. Infusing 0.1µM nicotine or vehicle into the NAcc did not 
affect accumbal DA release. 
 
 
Figure 2: The effect of infusions in the NAcc shell (top panel) or VTA (bottom panel) with 
vehicle (open circles), 0.1µM nicotine (solid squares), 1µM nicotine (open squares), 10µM 
nicotine (solid circles), 100µM nicotine (open triangles), or 1000µM nicotine (solid 
triangles) on DA release in the NAcc shell. Infusions started at t=0 min and lasted for 260 





Nicotine infusions into the VTA via retrograde dialysis, only produced 
significant increases in DA release in the NAcc shell at concentrations over 
10µM (F(3,285)=7.629; p=0.001; figure 2). Infusions with 10µM had no 
effect, while 100µM and 1000µM nicotine increased DA release compared 
to vehicle treatment. Both treatments elevated DA release to about 150% of 




The NAcc shell is 100-times more sensitive to nicotine than the VTA 
In figure 3 the mean AUC with baseline subtraction is given for each dose 
infused in NAcc or VTA, from 0 to 260 minutes. When the local infusions 
into the VTA and NAcc are compared in a dose-response curve it shows that 
the response in the NAcc is 100-times more sensitive than in the VTA. Both 
brain areas show a plateau of nicotine-induced DA release which is reached 
within one order of magnitude. 
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Figure 3: Dose-response curve of nicotine infused in NAcc shell (solid 
circles) and VTA (open circles). Data represented are the AUC 
(%*min) plus SEM of each local infusion into NAcc or VTA (µM). 




Systemic nicotine increases VTA dopaminergic cell firing 
Administration of 0.1mg/kg i.v. nicotine showed a trend towards an increase 
in dopaminergic cell firing to 131% of pre-drug firing rates (figure 4). A 
lower nicotine dose (0.02mg/kg i.v.) was not effective. Administration of 
apomorphine (0.02mg/kg i.v.) decreased cell firing, this together with other 
criteria (position, waveform, firing rate) demonstrates that the cells 
monitored were indeed dopaminergic. 
The basal rate of DA neurons in the VTA was (mean ± SEM) 4.38 ± 0.84Hz 
(n=8). 
 


















Figure 4: The effect of systemic nicotine [0.02 and 0.1 mg/kg i.v. 
(grey)] on dopaminergic cell firing in the VTA. The effect of 
apomorphine [0.02 mg/kg i.v. (black)] demonstrates that dopaminergic 





This study presents a sensitive response to nicotine in the NAcc shell, 
indicating that this region might play an important role in nicotine induced 
reward. Infusing 1µM nicotine into the NAcc shell resulted in an increase in 
accumbal DA to about 150% of basal. Infusing 100µM nicotine into the 
VTA increased accumbal DA to similar level as the 1µM NAcc shell 
infusion. These findings provide evidence that the current hypothesis of 
nicotine-induced reward might not be complete and the NAcc may play a 
more important role than previously thought. Therefore, the nicotinergic 
interaction with nAChRs, resulting in the all important rewarding accumbal 
DA release, might take place in the NAcc rather than in the VTA. 
Conversely, other microdialysis and electrophysiological studies in 
knockout mice demonstrated that the primary effect of nicotine is 
stimulation of DA cell firing by local action in the VTA (Hildebrand et al., 
1999; Maskos et al., 2005; Nisell et al., 1994a, b). Selective activation of 
α4β2 nAChRs (the most abundant subtype in the VTA), induced rewardive 
effects shown with a systemic nicotine self-administration model (Pons et 
al., 2008), and in a CPP test (Tapper et al., 2004). However, in accordance 
with this and other studies the α7-nAChR in the NAcc is of high importance 
(Fu et al., 2000; Harfstrand et al., 1988; Kamiya et al., 1982). Blocking the 
nAChRs in the NAcc using the α7 specific antagonist α-bungarotoxin, the 
systemic nicotine-evoked DA release in the NAcc was reduced by 50% (Fu 
et al., 2000). These results indicate that at least part of the nicotine-induced 
increase in mesolimbic DA is the result of an interaction of nicotine with the 
NAcc nAChRs. Since diverse types of nAChRs are present in both the VTA 
and the NAcc, of which in reward the α4β2 and α7 are particularly implicated 
(Fu et al., 2000; Laviolette and van der Kooy, 2003; Maskos et al., 2005; 
Panagis et al., 2000; Picciotto et al., 1998; Walters et al., 2006). It is 
probably the ratio between receptor densities of these nAChR subtypes that 
dictates the effect of the VTA and NAcc in reward. 
 
This study shows a dose response for nicotine infusions in both the NAcc 
and VTA. The concentrations used in this study are previously reported 
although never in one single study (Mifsud et al., 1989; Nisell et al., 1994a, 
b). The 1µM and 10µM infusions into the NAcc shell increase accumbal 
DA, in line with previous studies (Mifsud et al., 1989). Misfud et al. have 
shown that infusion of 2.4µM nicotine into the NAcc area increased DA 
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release to 490%. Although these authors report an increase in DA after 
2.4µM nicotine infusion, the magnitude of their increase is far higher than 
ours. This discrepancy between responses may be explained by essential 
methodological differences between the studies (higher calcium 
concentration in Ringers solution, shorter recovery after surgery). 
 
VTA nicotine infusion concentrations of 100µM and 1000µM are required 
to evoke an increase in DA in the ipsilateral NAcc to about 150% of basal, 
as supported by previous reports (Nisell et al., 1994a, b). After infusing 
nicotine (1000µM) into the VTA or NAcc the increase in DA has been 
reported to be more pronounced when nicotine was infused in the VTA than 
in the NAcc (Nisell et al., 1994a). However in another study, NAcc nicotine 
(1000µM) infusions increase NAcc DA release to the same level (~150%) as 
the VTA nicotine (1000µM) infusions (Nisell et al., 1994b). Although the 
VTA infusions in the results of this study show a comparable DA response, 
which validate the model, the main difference between the study results are 
the effective doses in the NAcc. This discrepancy might be explained by the 
sub-region of the NAcc in which DA was monitored. The present study 
sampled the NAcc shell region specifically, where Nisell et al. placed the 
probe more lateral from midline and therefore positioned the probe more in 
the core region of the NAcc. As drugs of abuse preferentially increase DA in 
the NAcc shell, compared to the core region (Pontieri et al., 1995; Pontieri 
et al., 1996; Tanda et al., 1997). It seems crucial to study the dopaminergic 
response to nicotine in the NAcc shell region, an argument strengthened by 
a study where the NAcc shell was shown to be more responsive to systemic 
nicotine, in increasing DA release, compared with the NAcc core in acute 
and chronically pretreated rats (Nisell et al., 1997).  
 
In this study we found a clear difference between effective nicotine dose in 
the NAcc shell and VTA, on increasing accumbal DA release (see figure 3). 
Both the NAcc and VTA show a similar pattern reaching a maximum 
nicotine-induced DA release within one order of magnitude. It is expected 
that higher nicotine concentrations are needed to saturate the VTA, in a dual 
probe experiment, to elicit a maximal increase of extracellular DA in the 
NAcc (Westerink et al., 1992). However, the likelihood that this is the main 
explanation for the difference in responsiveness between NAcc and VTA is 
small, since the time to reach the maximal accumbal dopaminergic response 
is similar in both brain areas. 
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Following a pharmacologically active dose of 0.32mg/kg s.c. nicotine, DA 
release was significantly increased in the NAcc shell region, but not in the 
VTA. DA release in the VTA is probably of dendritic origin and indicates, 
in freely moving animals, an increase in neuronal activity (Kalivas and 
Duffy, 1991). To further examine the role of nicotine on dopaminergic 
activity in the VTA, the effect of systemic nicotine on VTA DA cell firing 
was monitored. After a relatively high nicotine dose (0.1mg/kg i.v.) only a 
trend to an increased cell firing (to 131% of controls) was observed. While 
the lower dose of 0.02mg/kg i.v. had no effect. These results are in line with 
a study where similar and even higher doses of nicotine (up to 0.775mg/kg 
i.v.) were used to stimulate dopaminergic firing in rats (Pierucci et al., 
2004). Although, these results are at odds with a study in β2 knock-out mice 
(Maskos et al., 2005), in which 0.03mg/kg i.v. nicotine significantly 
increased dopaminergic cell firing in the mouse VTA. These discrepancies 
might be explained by species differences. This would mean that VTA 
neurons in the rat are less responsive to nicotinic stimulation than those in 
mice, and could therefore differentially regulate DA release after i.v. 
nicotine administration. 
For the understanding of reward the distinction between the NAcc shell and 
core is important. Similarly it has been suggested that the VTA displays 
distinct functions in reward processes when the anterior or posterior VTA 
are compared. E.g., it was shown that applying the nAChR antagonist 
mecamylamine in the anterior VTA completely blocked the increase in 
accumbal DA release seen after systemic ethanol administration(Ericson et 
al., 2008; Tizabi et al., 2002), whereas mecamylamine in the posterior VTA 
was ineffective (Ericson et al., 2008). Therefore the location within the 
VTA, might be critical and could explain the moderate dopaminergic 
response on firing rate of DA neurons as observed in this study. 
 
The dose-response presented here for local nicotine infusion shows that the 
NAcc shell is more sensitive to nicotine than the VTA in increasing 
accumbal DA release. This provides evidence that the current hypothesis of 
nicotine-induced reward might not be complete and the NAcc could play a 
more important role than previously proposed. Therefore it is recommended 
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The psychostimulant drug amphetamine is often prescribed to treat 
Attention-Deficit/Hyperactivity Disorder. The behavioral effects of the 
psychostimulant drug amphetamine depend on its ability to increase 
monoamine neurotransmission in brain regions such as the nucleus 
accumbens (NAC) and medial prefrontal cortex (mPFC). Recent behavioral 
data suggest that the endocannabinoid system also plays a role in this 
respect. Here we investigated the role of cannabinoid CB1 receptor activity 
in amphetamine-induced monoamine release in the NAC and/or mPFC of 
rats using in vivo microdialysis. Results show that systemic administration 
of a low, clinically relevant dose of amphetamine (0.5 mg/kg) robustly 
increased dopamine and norepinephrine release (to ~175-350% of baseline 
values) in the NAC shell and core subregions as well as the ventral and 
dorsal parts of the mPFC, while moderately enhancing extracellular 
serotonin levels (to ~135% of baseline value) in the NAC core only. 
Although systemic administration of the CB1 receptor antagonist 
SR141716A (0-3 mg/kg) alone did not affect monoamine release, it dose-
dependently abolished amphetamine-induced dopamine release specifically 
in the NAC shell. SR141716A did not affect amphetamine-induced 
norepinephrine or serotonin release in any of the brain regions investigated. 
Thus, the effects of acute CB1 receptor blockade on amphetamine-induced 
monoamine transmission were restricted to dopamine, and more 
specifically to mesolimbic dopamine projections into the NAC shell. This 
brain region- and monoamine-selective role of CB1 receptors is suggested 







The psychostimulant drug amphetamine is not only one of the leading 
prescription drugs to treat Attention-Deficit/Hyperactivity Disorder 
(ADHD) (Elia et al., 1999; Kutcher et al., 2004; Swanson et al., 2011), but 
also a widely abused addictive substance (Costa e Silva, 2002; Miller et al., 
1989). Amphetamine’s behavioral effects are known to depend on its ability 
to robustly enhance monoamine transmission throughout the brain 
(Fleckenstein et al., 2007; Robertson et al., 2009). Other neurotransmitter 
systems have, however, been implicated as well, including the endogenous 
cannabinoid system.  
 
Endocannabinoids (eCBs), which via the cannabinoid CB1, and to a lesser 
extent CB2, receptors function as a negative feedback mechanism in the 
brain (Iversen, 2003; Kano et al., 2009), have particularly been implicated 
in mediating amphetamine-induced locomotor activity (Pryor et al., 1978; 
Tzavara et al., 2003; 2009), psychomotor sensitization (Corbille et al., 
2007; Thiemann et al., 2008a; 2008b), and the persistence of 
psychostimulant addiction (Wiskerke et al., 2008). Moreover, we recently 
showed that the effects of a low dose of amphetamine on impulsive 
behaviors in rats can be prevented by pharmacological blockade of CB1 
receptors (Wiskerke et al., 2011b). Together, these findings underscore that 
activation of the eCB system may represent a mechanism subserving 
amphetamine-induced behaviors. Indeed, acute challenges with 
amphetamine have been shown to modulate eCB levels in several brain 
regions including the nucleus accumbens (NAC) (Thiemann et al., 2008a). 
Putative involvement of eCBs in amphetamine-induced behaviors is 
presumably related to the close interactions that exist between the eCB and 
monoamine neurotransmitter systems in the brain. Thus, there is ample 
evidence for functional interactions of the eCB system with dopamine 
(DA), norepinephrine (NE), and serotonin (5-HT) systems within brain 
areas such as the medial prefrontal cortex (mPFC) and NAC (Egerton et al., 
2006; Lopez-Moreno et al., 2008; Schlicker and Kathmann, 2001). In 
addition, a large literature already exists on the role of CB1 receptors in the 
effects of various other abused substances on specifically NAC DA release, 
effects that in contrast to those of amphetamine depend on DA neural 
activity (Cheer et al., 2007; Serrano and Parsons, 2011). In general, 
although the results from studies employing CB1 receptor knockout mice 
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have sometimes yielded mixed results, pharmacological studies have shown 
that acute CB1 receptor blockade reduces alcohol- and nicotine-induced, 
but not opiate- or cocaine-induced, tonic DA release in the NAC (for 
review, see Serrano and Parsons, 2011). In contrast, the CB1 receptor 
antagonist SR141716A has recently been shown to abolish transient DA 
release induced by alcohol, nicotine, and cocaine in rats (Cheer et al., 
2007).  
 
Given the vast amount of studies indicating CB1 receptor involvement in 
amphetamine-induced behaviors and the occurrence of eCB-monoamine 
interactions in the brain, surprisingly little is known about the role of CB1 
receptors in amphetamine-induced monoamine release that is independent 
of DA neural activity (Sulzer, 2011). In order to examine such a modulatory 
role of the eCB system and its possible monoamine- and brain region-
specificity, we investigated the effects of behaviorally relevant doses of 
SR141716A (De Vries et al., 2001; Pattij et al., 2007; Wiskerke et al., 
2011b) on amphetamine-induced increases in monoamine release in the 
NAC and mPFC. To that end, we used in vivo microdialysis to monitor the 
release of DA, NE, and 5-HT in the NAC shell and core subregions and the 
ventral and dorsal parts of the mPFC of freely moving rats following 
administration of SR141716A (0-3 mg/kg) alone and in combination with a 
low dose of amphetamine (0.5 mg/kg). A low dose of the latter drug was 
chosen given its clinical relevance (Elia et al., 1999; Kutcher et al., 2004) 
and because this dose is devoid of stereotypy effects (Kuczenski et al., 
1991). Moreover, we recently showed that impulsive behavior in rats 
induced by this dose of amphetamine is CB1 receptor-dependent (Wiskerke 




Material and Methods 
 
Animals  
Male Wistar rats (275-320g; Harlan, The Netherlands) were used. After 
surgery, animals were individually housed in plastic cages (35x35x40cm). 
Animals were maintained at approximately 90% of their free-feeding 
weight starting 1 week prior to the beginning of the experiments by 
restricting the amount of standard rodent food pellets (Harlan Teklad 
Global Diet, Blackthorn, UK). Water was available ad libitum throughout 
the entire experiment. The experiments were conducted during the dark 
phase (19:00h – 07:00h) in a temperature (22 ± 2˚C) and humidity (55 ± 10 
%) controlled room. Experiments were approved by the ethical committee 
of the University of Groningen (the Netherlands), and all efforts were made 
to minimize animal suffering, to reduce the number of animals used, and to 
utilize alternatives to in vivo techniques, if available. 
 
Drugs and drug treatment 
SR141716A was kindly donated by Abbott (Weesp, the Netherlands), and 
dissolved as previously described (De Vries et al., 2001) in a mixture of 
ethanol, TWEEN80, and sterile saline in a ratio 1:1:18. (+)-Amphetamine-
sulphate (O.P.G., Utrecht, the Netherlands) was dissolved in sterile saline. 
Amphetamine and SR141716A were freshly prepared on each testday and 
injected intra-peritoneally (i.p.) in a volume of 1 ml/kg bodyweight.    
 
Surgery and in vivo microdialysis 
Each rat was equipped with two microdialysis probes: one probe in the 
NAC (either shell or core subregion) and one in the mPFC (either ventral or 
dorsal part). Both microdialysis probes were implanted simultaneously 
under isoflurane anesthesia (2.5%, 0.6l/min (O2)) and local analgesia with 
bupivacaine and finadyne (2mg/kg, 1ml/kg s.c.) for postoperative analgesia. 
For the ventral and dorsal mPFC I-shaped 6mm long microdialysis probes 
(2mm exposed membrane; polyacrylonitril, MW cut-off 40-50kDa; 
Brainlink, the Netherlands) were implanted (coordinates from bregma and 
dura;Paxinos and Watson, 2007: A/P 3.0, L/M 1.0 (angle: 5˚), V/D -4.1 and 
A/P 3.0, L/M 0.8 (angle: 5˚), V/D -2.4, respectively). For the NAC shell 
and core (A/P 2.0, L/M 0.9, V/D -7.9 and A/P 1.6, L/M 1.8, V/D -7.7, 
respectively) 9mm long I-shaped microdialysis probes were implanted (1.5 
mm exposed membrane; polyacrylonitril, MW cut-off 40-50kDa; Brainlink, 
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the Netherlands). After surgery (performed on Fridays) animals were 
allowed to recover for 48h. Subsequently, all animals were tested in two 
microdialysis experiments, conducted on the following Monday and Friday 
to ensure that drugs administered on the first test-day would not interfere 
with the second test-day. Each animal was tested once using the probe in 
the nucleus accumbens (shell or core) and once using the probe in the 
mPFC (dorsal or ventral part), in a semi-random order, to reduce the 
number of rats required for this study. The drug dosages administered on 
each test-day were also chosen semi-randomly so no animal would receive 
the same treatment twice and to prevent any treatment-order effects. 
 
Microdialysis experiments were carried out by perfusing the probes with 
Ringer’s solution (in mM: NaCl 140.0, KCl 4.0, CaCl2 1.2, MgCl2 1.0) at a 
flow rate of 1.5µl/min (CMA402 syringe-pump, CMA microdialysis). 15 
min samples were collected using a fraction collector (Univentor820 
microsampler, TSE systems) and samples were stored at -80oC until 
analysis. The experiment started with the collection of four baseline 
samples followed by administration of SR141716A (1 or 3 mg/kg i.p., 
doses based on our previous work (De Vries et al., 2001; Pattij et al., 2007; 
Wiskerke et al., 2011b)) or vehicle. Another four samples were taken to 
determine the effect of SR141716A on monoamine release, after which 
amphetamine (0.5 mg/kg i.p., dose based on our previous work 
(Schoffelmeer et al., 2002; Wiskerke et al., 2011a; 2011b)) was 
administered and the effect of the drug interaction on monoamine release 
was monitored for 3 hours. At the end of the experiment, the animals were 
euthanized using an overdose of pentobarbital (20%) and probe placement 
was histologically evaluated. 
 
Monoamine analysis 
Complete sample dialysate monoamine content was determined as 
previously described (Rollema et al., 2011) using a Shimadzu LC-10-ADvp 
setup connected with Sciex API4000 MS/MS units (Applied Biosystems, 
the Netherlands). Chromatographic separation was performed using a 
reversed phase Synergi MAX-RP 100 x 3 (2.5µm particle size) column. 
Through soft ionization components were analyzed in the MS/MS with high 
sensitivity (LOQ: 0.05 nM) and selectivity. Data acquisition was performed 





For each analyte baseline samples (t=-60 to 0 min) of each drug treatment 
group were  submitted to a one-way analysis of variance (ANOVA) for 
repeated measures per brain region with drug dose as between subjects 
factor, to exclude possible group differences. Subsequently, microdialysis 
data were expressed as percentages of baseline. To evaluate the effect of 
amphetamine on monoamine release in subregions of the NAC and mPFC, 
per brain region a repeated measures ANOVA was executed for each 
analyte with time as within subjects variable, followed by Student Newman 
Keuls post-hoc analyses to determine individual time point differences 
whereby t=60 min was used as a control value. For the effect of drug 
(amphetamine + SR141716A) treatment, statistical analysis was performed 
per analyte per brain region with a two-way repeated measures ANOVA, 
testing for the effect of drug dose and time, followed by Student Newman 
Keuls post-hoc analyses. In these analyses, to determine the effects of 
SR141716A alone, samples collected between t=0-60 min were analyzed, 
whereas for the effects of SR141716A on amphetamine-induced 
monoamine release samples collected between t=60-240 min were 






The effects of administration of SR141716A (1 or 3 mg/kg) on monoamine 
release induced by acute amphetamine administration (0.5 mg/kg) were 
assessed by in vivo microdialysis in the NAC shell and core sub regions, as 
well as the ventral and dorsal parts of the mPFC. There were no significant 
differences between baseline values of any of the monoamines (DA, NE, or 
5-HT) among different doses within one brain area. The pooled baseline 
monoamine levels per brain region recovered in this study are presented in 
table 1. 
 
Table 1: Mean basal monoamine levels in brain dialysates (not corrected for recovery) 
             Monoamine            Brain area            fmol/sample  
                 (± SEM) 
            n =  
                (total) 
            F-value  
            (treatment-effect) 
              Dopamine              NAC shell           61.0 ± 8.6              19              F(2,10)= 0.58; N.S. 
             NAC core            47.4 ± 4.4              19              F(2,10)= 0.23; N.S. 
         ventral mPFC            8.4 ± 1.7              20              F(2,10)= 0.72; N.S.                  
            dorsal mPFC           8.3 ± 1.6              20              F(2,10)= 3.21; N.S. 
           Norepinephrine            NAC shell           7.0 ± 0.8              16              F(2,8)= 1.08; N.S. 
            NAC core            7.4 ± 1.4              16              F(2,10)= 1.02; N.S. 
            ventral mPFC            10.7 ± 0.9              16              F(2,8)= 0.25; N.S. 
            dorsal mPFC          11.8 ± 1.4              17              F(2,9)= 3.21; N.S. 
                  5-HT             NAC shell           4.0 ± 0.3              19              F(2,10)= 0.48; N.S. 
            NAC core            4.4 ± 0.6              19              F(2,10)= 0.48; N.S. 
         ventral mPFC            3.5 ± 0.3              19              F(2,10)= 1.24; N.S. 







SR141716A dose-dependently blocks amphetamine-induced DA release 
in the NAC shell 
Results from separate analyses over the pre-amphetamine period (t=0-60 
min) showed that neither dose of SR141716A alone altered DA levels in 
any of the brain areas monitored (figure 1; Treatment effects: NAC shell: 
F(2,59)=2.71, N.S.; NAC core: F(2,64)=3.56, N.S.; ventral mPFC: F(2,64)=0.47, 
N.S.; dorsal mPFC: F(2,66)=1.28, N.S.). In contrast, separate analyses of the 
amphetamine-vehicle treated animals showed that amphetamine increased 
extracellular DA levels in the NAC shell and core to approximately 200% 
of baseline (shell: F(12,60)=14.78, p<0.001; core: F(12,60)=18.51, p<0.001), 
with post-hoc testing revealing a significant amphetamine effect between 
t=90-165 min in both subregions of the NAC. In the ventral and dorsal parts 
of the mPFC amphetamine caused increases of ~270% and ~190%, 
respectively (ventral mPFC: F(12,43)=6.92, p<0.001; dorsal mPFC: 
F(12,59)=3.65, p<0.001). Post-hoc testing revealed that amphetamine 
increased mPFC dopamine release between t=90-105 min.  
 
 
Figure 1: Effects of the CB1 receptor antagonist SR141716A (1 mg/kg (open circle), 3 
mg/kg (closed triangle); i.p.) or vehicle (closed circle), administered at t=0 min, on DA 
release induced by amphetamine (0.5 mg/kg;  i.p.; administered at t=60 min) in the NAC 
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shell (upper left), NAC core (upper right), ventral mPFC (lower left) and dorsal mPFC 
(lower right). Data are expressed as mean percentage DA release of baseline ± SEM (n=5-
7 per treatment per brain region). Asterisks indicate p<0.05 as compared to the vehicle. 
 
Only in the NAC shell, prior administration of SR141716A dose-
dependently affected amphetamine-induced DA release with statistical 
analyses showing significant treatment (F(2,184)=5.51, p=0.015), time 
(F(12,184)=14.94, p<0.001), and treatment × time effects (F(24,184)=1.67, 
p=0.033). Further comparisons revealed that particularly from 30 to 90 
minutes following amphetamine administration (t=90-150 min) there was a 
significant reduction in amphetamine-induced DA release after 
administration of 3 mg/kg SR141716A versus vehicle administration. In 
fact, prior administration of 3 mg/kg SR141716A completely prevented 
amphetamine-induced increments in NAC shell DA release (F(12,55)=1.94, 
N.S.). For all other brain regions, SR141716A did not affect amphetamine 
induced DA release (Treatment: NAC core: F(2,191)=2.60, N.S.; ventral 
mPFC: F(2,181)=0.28, N.S.; dorsal mPFC: F(2,190)=0.22, N.S.). 
 
 
SR141716A does not affect amphetamine-induced NE release in the NAC 
or mPFC  
In the amphetamine-vehicle treated animals, acute administration of 
amphetamine increased extracellular NE levels in all brain areas monitored 
(figure 2). The relative increase in extracellular NE was most pronounced in 
the mPFC, with an increase of ~345% (F(12,48)=7.34, p<0.001; significant 
post hoc tests between t=90-135 min) and ~220% (F(12,48)=8.07, p<0.001; 
significant post hoc tests between t=90-120 min) as compared to baseline in 
the ventral and dorsal mPFC, respectively. In the NAC shell and core, 
amphetamine increased NE levels to ~205% (F(12,48)=7.69, p<0.001; 
significant post-hoc tests between t=90-135 min), and 175% (F(12,48)=4.00, 
p<0.001; significant post-hoc tests between t=75-240 min) of baseline 
values, respectively. Prior administration of SR141716A did not affect 
amphetamine-induced NE release (Treatment: NAC shell: F(2,139)=0.19, 
N.S.; NAC core: F(2,155)=0.21, N.S.; ventral mPFC: F(2,140)=0.39, N.S.; 
dorsal mPFC: F(2,157)=0.21, N.S.). Furthermore, SR141716A alone did not 
affect NE levels in any brain area monitored (Treatment: NAC shell: 
F(2,45)=2.47, N.S.; NAC core: F(2,52)=1.19, N.S.; ventral mPFC: F(2,48)=0.52, 





Figure 2: Effects of the CB1 receptor antagonist SR141716A (1 mg/kg (open circle), 3 
mg/kg (closed triangle) i.p.) or vehicle (closed circle) administered at t=0 min, on NE 
release induced by amphetamine (0.5 mg/kg i.p.; administered at t=60 min) in the NAC 
shell (upper left), NAC core (upper right), ventral mPFC (lower left) and dorsal mPFC 
(lower right). Data are expressed as mean percentage NE release of baseline ± SEM (n=5-6 
per treatment per brain region). 
 
 
Amphetamine moderately increases 5-HT levels in the NAC core via a 
CB1 receptor-independent mechanism 
During the 300 min of sampling the levels of 5-HT did not deviate more 
than 50% from baseline values in any brain region monitored. Nonetheless, 
administration of amphetamine (0.5 mg/kg) in the amphetamine-vehicle 
group resulted in a significant increase in 5-HT release in the NAC core 
(figure 3; F(12,54)=3.47, p<0.001). Post-hoc analysis revealed that only at 
t=105 min the level of extracellular 5-HT was significantly increased to 
~135% of baseline. In the NAC shell, a one-way ANOVA for repeated 
measures revealed a time effect in the amphetamine-vehicle group 
(F(12,57)=3.40, p<0.001). However, further analyses did not identify any time 
point to be significantly different from baseline (t=60 min) in this brain 
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region, thereby questioning the biological relevance of this finding. In the 
mPFC, administration of amphetamine had no effect on 5-HT levels 
(ventral mPFC: F(12,57)=1.34, N.S.; dorsal mPFC: F(12,57)=0.48, N.S.). 
Furthermore, there was no effect of administration of SR141716A alone on 
extracellular 5-HT levels in any brain region (Treatment: NAC shell: 
F(2,57)=1.29, N.S.; NAC core: F(2,59)=1.80, N.S.; ventral mPFC: F(2,64)=0.65, 
N.S.; dorsal mPFC: F(2,63)=0.83, N.S.). Likewise, no significant effects were 
detected of SR141716A followed by amphetamine on 5-HT release in the 
NAC or mPFC (Treatment: NAC shell: F(2,166)=0.49, N.S.; NAC core: 





Figure 3: Effects of the CB1 receptor antagonist SR141716A (1 mg/kg (open circle), 3 
mg/kg (closed triangle) i.p.) or vehicle (closed circle) administered at t=0 min, on 5-HT 
release induced by amphetamine (0.5 mg/kg i.p.; administered at t=60 min) in the NAC 
shell (upper left), NAC core (upper right), ventral mPFC (lower left) and dorsal mPFC 
(lower right). Data are expressed as mean percentage 5-HT release of baseline ± SEM 





In the present study, we examined the in vivo effects of the cannabinoid 
CB1 receptor antagonist SR141716A on amphetamine-induced monoamine 
release in the NAC and mPFC by challenging rats systemically with a low 
dose (0.5 mg/kg) of amphetamine. Such a dose of amphetamine is clinically 
relevant (Elia et al., 1999; Kutcher et al., 2004) and has previously been 
shown in rats to robustly enhance locomotor activity (Schoffelmeer et al., 
2002) and to affect impulsivity (van Gaalen et al., 2006a; 2006b; Wiskerke 
et al., 2011a; 2011b) in rats without causing stereotyped behaviors 
(Kuczenski et al., 1991) under our experimental conditions. 
 
The locomotor activating and addiction-related behavioral effects of 
psychostimulants, such as amphetamine, are known to be mediated by the 
mesocorticolimbic monoamine systems (Fleckenstein et al., 2007; 
Robertson et al., 2009) in concordance with other neurotransmitter systems, 
including the eCB system (Corbille et al., 2007; Pryor et al., 1978; 
Thiemann et al., 2008a; 2008b; Tzavara et al., 2003; 2009; Wiskerke et al., 
2008). Moreover, we recently showed that the effects of a low dose of 
amphetamine (0.5 mg/kg) on measures of impulsive behavior in rats could 
be reversed by pre-treatment with the CB1 receptor antagonists 
SR141716A and O-2050 (Wiskerke et al., 2011b). Despite this large body 
of behavioral evidence supporting a role for CB1 receptor activity in 
amphetamine’s effects, data on the underlying mechanisms are scarce.  
 
Several brain regions of the mesocorticolimbic system including the mPFC 
and particularly the NAC have been implicated in amphetamine’s actions 
on the eCB system (Hiranita et al., 2008; Rodriguez et al., 2011; Thiemann 
et al., 2008a). Furthermore, to our knowledge, only a single study has 
reported on the role of the eCB system in amphetamine-induced 
monoamine release, showing that genetic deletion of the CB1 receptor did 
not influence DA release in the NAC of mice following an acute 
amphetamine challenge (Tzavara et al., 2009). In contrast, we observed that 
pretreatment with SR141716A dose-dependently abolished the 
amphetamine-induced increase in DA release specifically in the NAC shell. 
This apparent discrepancy between our data and those of Tzavara and co-
workers (2009) may well be due to the fact that these researchers used 
constitutive CB1 receptor knockout mice, whereas in the current study the 
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effects of acute pharmacological blockade of CB1 receptors on 
amphetamine-induced monoamine release were studied. Importantly, our 
findings were not resulting from homergic effects of SR141716A and 
amphetamine on DA transmission, since SR141716A by itself did not 
significantly affect DA release in the NAC shell.  In fact, administration of 
SR141716A alone did not significantly affect monoamine release in the 
NAC or mPFC, suggesting absence of an eCB tone regulating monoamine 
transmission in these brain regions under our experimental conditions as 
previously reported by others (e.g. Kleijn et al., 2011; Nakazi et al., 2000; 
Oropeza et al., 2005; Pistis et al., 2002; Solinas et al., 2006). Two earlier 
studies, however, did show stimulatory effects of SR141716A on 
monoamine release in both the mPFC and NAC (Need et al., 2006; Tzavara 
et al., 2003). It is possible that differences in experimental design, including 
route, dose, and volume of drug administration and the microdialysis 
technique employed explain this discrepancy in findings. Indeed, in both 
aforementioned studies, effects of SR141716A on monoamine release were 
mainly observed at a dose of 10 mg/kg. However, behavioral effects of 
SR14716A in rodents are usually already observed within a dose range of 
1-3 mg/kg (De Vries et al., 2001; Pattij et al., 2007; Thiemann et al., 2008b; 
Tzavara et al., 2003; 2009; Wiskerke et al., 2011b). Hence, we here did not 
test higher doses,  even though we acknowledge that different results may 
have been obtained with higher doses of SR141716A. It should also be 
mentioned that SR141716A is thought to have inverse agonistic properties 
under certain experimental conditions, i.e. that in the absence of an 
endogenous tone at the CB1 receptor it may have effects opposite to those 
of a CB1 receptor agonist, probably due to a reduction of constitutive 
receptor activity (Pertwee, 2005). Although a contribution of such effects to 
the current results cannot be ruled out at present, they are unlikely to fully 
explain our results given that we recently excluded a role for the inverse 
agonistic properties of SR141716A in dopamine-dependent behavior. Thus, 
under similar experimental conditions employed here, we fully replicated 
the effects of SR141716A on impulsive behaviors in rats with the neutral 
CB1 receptor antagonist O-2050 (Wiskerke et al., 2011b).  
 
The effects of SR141716A on amphetamine-induced monoamine release 
were restricted to DA transmission, as amphetamine-induced NE and 5-HT 
release were not affected by SR141716A pretreatment in the brain regions 
monitored. It should be noted here that, in contrast to the effects on DA and 
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NE and in line with previous studies (Baumann et al., 2011; Dalley et al., 
2002; Pum et al., 2007), the effects of amphetamine on 5-HT release were 
moderate, which may be related to the lower affinity of amphetamine for 
the 5-HT transporter versus the DA and NE transporter (Rothman and 
Baumann, 2003). Therefore, although we cannot exclude the possibility that 
SR141716A might reduce amphetamine-induced 5-HT release when higher 
doses of the psychostimulant, that do increase 5-HT release (Baumann et 
al., 2011; Kuroki et al., 1996), are administered, it seems safe to conclude 
that an interaction between the eCB and 5-HT systems does not play a 
major role in the robust locomotor and neurocognitive effects of low doses 
of amphetamine. Altogether, our data suggest that under our experimental 
conditions, which were specifically designed to match the experimental 
conditions in our recent study on the role of the CB1 receptor in 
amphetamine-induced impulsivity (Wiskerke et al., 2011b), CB1 receptor 
activation mediates the behavioral effects of amphetamine primarily by 
enhancing DA release in the NAC shell. 
 
Our study is not the first to show that CB1 receptors can control tonic DA 
release in the NAC shell induced by a drug of abuse (for review, see 
Serrano and Parsons, 2011). In addition, acute SR141716A-treatment was 
previously found to reduce alcohol-, nicotine-, and cocaine-induced DA 
transients into the NAC shell of rats (Cheer et al., 2007). The current results 
confirm and extend those findings by showing that CB1 receptors also 
modulate amphetamine-induced tonic DA release. In contrast to those of 
other drugs of abuse, the DA-releasing effects of amphetamines are 
independent of vesicle exocytosis at DA terminals. Thus, amphetamines 
induce robust DA release via reversed transport of cytosolic DA through 
the DA transporter in combination with a complex series of intracellular 
actions including effects on DA-related enzymes and molecules such as 
tyrosine hydroxylase, monoamine oxidase, and vesicular monoamine 
transporter-2 (for excellent reviews on this subject, see e.g. Fleckenstein et 
al., 2007; Robertson et al., 2009; Sulzer, 2011). Our findings therefore 
suggest that CB1 receptor modulation of drug-induced alterations in DA 
release is independent of the propagation of action-potentials in DA 
neurons. Instead, the current findings together with the abovementioned 
previous findings suggest that eCB involvement in drug-induced DA 
transmission is heavily dependent on the release pattern and the anatomical 
locus of DA release.  In this respect it is of interest that the current effects 
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of SR141716A were found to be restricted to mesolimbic, but not 
mesocortical DA projections. The observed lack of effect of prior 
SR141716A administration on amphetamine-induced mPFC DA release 
was somewhat surprising given that both endogenous and exogenous CB1 
receptor agonists have consistently be shown to enhance basal DA release 
in the NAC as well as the mPFC (Chen et al., 1990a; 1990b; Oropeza et al., 
2005; Solinas et al., 2006; Tanda et al., 1997). On the other hand, our 
finding that CB1 receptor control over mesolimbic DA release is selective 
for the NAC shell is consistent with a previous study showing that CB1 
receptor agonists induced DA release in the NAC shell but not the NAC 
core (Tanda et al., 1997).  
 
It is as yet unclear how CB1 receptors modulate amphetamine-induced, 
action potential-independent DA release. This might include G-protein-
mediated inhibition of one or more of the presynaptic processes in DA 
nerve terminals acted upon by amphetamine to induce non-vesicular DA 
release. CB1 receptors are densely expressed in the NAC shell (Pickel et 
al., 2006; Wenger et al., 2003). However, DA neurons are generally 
believed to be devoid of CB1 receptors (Herkenham et al., 1991; Mailleux 
and Vanderhaeghen, 1992; Matsuda et al., 1993), albeit there is some 
inconsistency in the literature in this respect (Pickel et al., 2006; Wenger et 
al., 2003). Assuming that DA terminals are devoid of CB1 receptors, one 
must assume that activation of CB1 receptors reduces the negative feedback 
regulation of DA neural activity. Since drugs were administered 
systemically in the present study, the anatomical locus of the CB1 receptors 
involved in amphetamine-induced enhancement of DA levels in the NAC 
shell also remains elusive. Therefore, SR141716A may inhibit 
amphetamine-induced DA transmission indirectly by modulating 
glutamatergic and particularly GABAergic neurotransmission within the 
NAC shell or one of its afferent structures (Lopez-Moreno et al., 2008; 
Sperlagh et al., 2009). Perhaps noteworthy in this regard is the observation 
that infusion of SR141716A or its structural analogue AM251 into the NAC 
core, a brain region with GABAergic efferents to the NAC shell (van 
Dongen et al., 2005), suppressed methamphetamine-induced stereotypy 
(Morra et al., 2010). It is also conceivable that CB1 receptor blockade may 
have affected GABAergic and/or glutamatergic input onto the DA cell 
bodies in the ventral tegmental area (VTA) that innervate the NAC (Lupica 
and Riegel, 2005; Melis et al., 2004; Szabo et al., 2002). To resolve this 
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issue, future studies should combine in vivo microdialysis in the NAC shell 
with local infusion of CB1 receptor (ant)agonists in various 
mesocorticolimbic brain regions.  
 
In conclusion, we showed that systemic administration of the cannabinoid 
CB1 receptor antagonist SR141716A blocked the increase in DA release in 
the NAC shell but not in the NAC core, or the dorsal and ventral parts of 
the mPFC upon an acute challenge with a low dose of amphetamine. 
Moreover, the effects of this psychostimulant on NE and 5-HT release in 
the NAC and mPFC were unaffected by pharmacological blockade of CB1 
receptors. This monoamine- and brain site-specific role of CB1 receptors 
may subserve the psychomotor and neurocognitive effects of amphetamine. 
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A large percentage of depressed individuals uses drugs of abuse, like 
cannabis. This study investigates the impact of cannabis on the 
pharmacological effects of the antidepressant citalopram. Using 
microdialysis in the prefrontal cortex of rats we monitored serotonin levels 
before and after cannabinoid (WIN55,212-2 or rimonabant) and citalopram 
administration. Stimulating CB-1 decreased the effect of citalopram on 
increasing serotonin levels in the prefrontal cortex. Blocking CB-1 
augmented this effect of citalopram. Although repeating these experiments 
in a chronical setting is recommended the present results might have 














Predominantly amongst adolescents, there is a strong link between the use 
of drugs of abuse, especially cannabis, and mood disorders (Bovasso, 2001; 
Rey et al., 2002; Rey and Tennant, 2002). There are three hypotheses 
explaining this link. First, the self-medication hypothesis which states that 
the use of drugs, like cannabis, is a way to manage the depressive symptoms 
(Khantzian, 1985; Miller-Johnson et al., 1998). The second hypothesis 
suggests that comorbidity between cannabis dependence and depression 
likely arises from both genetic and environmental factors (Fu et al., 2002; 
Lynskey et al., 2004). The third hypothesis, states that high levels of 
cannabis use, especially during adolescence, trigger the onset of depression 
(Bovasso, 2001; Rey and Tennant, 2002). Whichever hypothesis is true, the 
facts remains that there is a comorbidity between cannabis use and 
depression (Kaminer et al., 2007; Rowe et al., 1995; Troisi et al., 1998). 
Furthermore, there are studies suggesting that depression has a negative 
effect on treatment outcomes of substance use disorder (Cornelius et al., 
2004; Riggs et al., 1995; Subramaniam et al., 2007). 
However, little is known about the influence of the use of “drugs of abuse”, 
like cannabis, on the effectiveness and outcome of treatment of depression 
using SSRI’s. Although various clinical studies have reported depressed 
patients using cannabis display poor illness treatment success rates (Raphael 
et al., 2005).  
 
In this rat study we asked whether stimulation or blocking the CB-1 receptor 
acutely modulates the effect of an acutely administered SSRI on 
extracellular serotonin (5-HT) levels in the brain. To answer this question 
we used microdialysis to sample the rat medial prefrontal cortex (mPFC) 
and LC-MS/MS to asses the 5-HT levels. Since the CB-1 receptors in the 
PFC are up-regulated in the PFC of rats subjected to different models of 
depression (Bortolato et al., 2007; Hill et al., 2008), we have chosen to focus 








Material and Methods 
 
All animal experiments were conducted according to the guidelines of the 
animal ethical committee of the University of Groningen. Male Wistar rats 
(225-325 g, Harlan; the Netherlands) were maintained on a 12 hour 
light/dark cycle.  
The CB-1 antagonist rimonabant (Kemprotec limited, Middlesbrough UK) 
and the CB-1 agonist WIN55,212-2 (Tocris Bioscience, UK) were 
suspended in 1% Tween80 in saline. Citalopram (provided by Lundbeck) 
was dissolved in saline. Rimonabant and citalopram were injected 
subcutaneous (s.c.1 ml/kg) and WIN55,212-2 was injected intraperitoneally 
(i.p.1 ml/kg). Rimonabant (1mg/kg) and WIN55,212-2 (1 mg/kg) were 
injected 30 minutes before citalopram was given on t=0 minutes. Based on 
earlier studies (Rea et al., 2010) a dose close to the EC 50% effect (3 mg/kg) 
of citalopram was chosen. No vehicle-vehicle group was included since 
similar experiments have shown no effect of vehicle treatment on baseline 
5-HT levels in the mPFC (Allers et al., 2010).  
 
Using isoflurane anesthesia, a microdialysis probe (Brainlink, The 
Netherlands) was positioned in the medial prefrontal cortex (mPFC; 
0.34AP; -0.08ML; -0.50DV mm relative to bregma and dura) according to 
the stereotaxic brain atlas (Praxinos and Watson, 2007). Ringers solution (in 
mM: NaCl 140.0, KCl 4.0, CaCl2 1.2, MgCl2 1.0) was used to perfuse the 
microdialysis probe (4 mm polyacrylonitrile membrane (cut-off 40-50 kDa) 
at a flow rate of 1.5 µl/min. After 2.5 hours of stabilization, collection of 20 
minute fractions was started.  
 
Analyses were performed on a Shimadzu LC-10-ADvp setup connected 
with Sciex API4000 MS/MS units. 5-HT and its internal standard, 5-HT-d4 
are derivatized with SymDAQ (Symmetrical DiAldehydes Quaternary ions) 
and through soft ionization analyzed with high sensitivity (LOQ: 0.05 nM) 
and selectivity. Data acquisition was performed using Analyst®1.4.2.  
 
All data were expressed as mean ± SEM and submitted to parametric tests 
(two-way analysis for repeated measures (ANOVA)), followed by Student 
Newman-Keuls method for post hoc comparisons. Statistical values 





To study the role of the CB-1 receptor on the effectiveness of citalopram to 
enhance mPFC extracellular 5-HT, we injected rats either the CB-1 receptor 
agonist WIN55,212-2 or the CB-1 receptor antagonist rimonabant followed 
by citalopram.  
There was no significant difference between groups in baseline serotonin 
levels (F(4,58)= 1,582; P<0.218). The overall baseline PFC 5-HT levels were 
(mean ± SEM in fMol/sample): 6.32 ± 0.71 (n = 25). 
 
CB-1 receptor agonist decreases the effect of citalopram on increasing 
mPFC 5-HT levels 
Co-administration of WIN55,212-2 ( 1 mg/kg i.p.) and citalopram ( 3 mg/kg 
s.c.) (n = 5) largely suppressed the citalopram-induced increase in 5-HT 
(figure 1), whereas WIN55,212-2 (n = 5) itself had no effect on extracellular 
5-HT levels in the mPFC (F(2,116) = 7,820; P<0.007). Citalopram (3 mg/kg, 
i.p.) increased mPFC 5-HT levels to about 420% of baseline, which started 
directly after administration, and was significantly higher compared to the 
other treatments during the first 80 minutes.  
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Figure 1: Effect of WIN55,212-2 (1mg/kg i.p.), alone, or in combination 
with citalopram (3mg/kg s.c.) on 5-HT levels in the mPFC. Filled circle: 
WIN55,212-2; open circle: citalopram; filled triangle: WIN55,212-2 + 
citalopram. Baseline 5-HT levels within groups were: WIN-VEH 5.79 ± 
 91 
0.75 (n = 5); WIN-CIT 8.63 ± 1.31 (n = 5); and VEH-CIT 7.90 ± 2.59 (n 
= 5) (mean ± SEM in fMol/sample). Data are expressed as percentage of 
baseline ± SEM (n=5).  * p<0.05 vs. other treatments. 5-HT levels were 
(mean ± SEM in fMol/sample): 6.32 ± 0.71 (n = 25). 
 
CB-1 receptor antagonist augments the effect of citalopram on 
increasing mPFC 5-HT levels 
Combining the CB-1 receptor antagonist rimonabant (1 mg/kg s.c.) with 
citalopram (3 mg/kg s.c.) resulted in the opposite effect on extracellular 
mPFC 5-HT levels (figure 2). This combination seemed to prolong and 
augment the effect of citalopram on 5-HT levels alone (F(20,110) = 4,711; 
P<0.001). While there was no overall difference between treatments 
administering citalopram alone and in combination with rimonabant, dosing 
the animals with both rimonabant and citalopram resulted in an significant 
increase in mPFC 5-HT levels compared to other treatments at t =100, 120, 























Figure 2: Effect of rimonabant alone, or in combination with 
citalopram on prefrontal cortex 5-HT levels. Filled circles: 
rimonabant (1mg/kg s.c.), open circles: citalopram (3mg/kg s.c.); 
filled triangles: rimonabant + citalopram. Baseline 5-HT levels 
within groups were: RIM-VEH 5.52 ± 1.24 (n = 5); RIM-CIT 3.77 ± 
0.74 (n = 5); and VEH-CIT 7.90 ± 2.59 (n = 5) (mean ± SEM in 
fMol/sample). Data are expressed as percentage of baseline ± SEM 





In our experiments, acute stimulation of the CB-1 receptors with 
WIN55,212-2 suppressed the effect of citalopram on increasing mPFC 5-HT 
levels. In contrast, blocking the CB-1 receptors with rimonabant augmented 
this effect of citalopram. 
 
The citalopram induced increase in extracellular 5-HT in the mPFC, to 
about 400 % of baseline, was clearly suppressed to only 200% of baseline 
by WIN55,212-2. In contrast, rimonabant enhanced the citalopram-induced 
increase in 5-HT levels, to about 550 % of baseline 120 minutes after 
citalopram administration. WIN55,212-2 or rimonabant alone did not affect 
extracellular 5-HT. This effect of rimonabant is in line with a study which 
showed that rimonabant in a dose of 1 mg/kg had no effect on 5-HT levels, 
although 3 mg/kg and 10 mg/kg both increased 5-HT efflux in the mPFC 
(Tzavara et al., 2003). That only high doses of rimonabant induce an effect 
on 5-HT release is supported by Darmani et al. who reported that an 
increase in 5-HT release after 20-40 mg/kg rimonabant (Darmani et al., 
2003).  
 
The present data suggest an interaction between the pharmacological effects 
of citalopram on extracellular 5-HT levels and the CB-1 receptor. The most 
likely explanation might be found in the assumption that a CB-1 agonist, 
even in the rather low dose of 1mg/kg i.p., is inhibiting the activity of 5-HT 
neurons in the mPFC resulting in less 5-HT available for uptake inhibition 
with citalopram. This explanation is supported by studies that show lower 
levels of serotonergic activity (Sagredo et al., 2006), release (Nakazi et al., 
2000), or the serotonin precursor 5-HTP (Moranta et al., 2009) in the 
prefrontal cortex after CB-1 agonist administration.  
A second, somewhat less likely explanation for the effect of WIN might be 
found in the assumption that CB-1 activation positively effects the transport 
of 5-HT and therefore directly counteracts the action of citalopram. This 
hypothesis is supported by a study that revealed a co-distribution of protein 
markers for monoamine release and re-uptake as well as CB-1 receptors on 
serotonergic neurons (Lau and Schloss, 2008). Lau et al. stated that, because 
of this co-expression, CB-1 receptors are able to inhibit serotonergic 
transport. Therefore, endogenous cannabinoids (ECs) could inhibit both 
release and reuptake of 5-HT by binding the CB-1 receptors. WIN55,212-2 
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might therefore regulate serotonergic release and reuptake, preventing the 
effect of citalopram, explaining our results. 
 
The inhibition by WIN55,212-2 of the citalopram-induced increase in 
extracellular 5-HT was immediate, whereas the augmentive effect of 
rimonabant was only detectable 100 minutes after the administration of  
citalopram. An explanation for this effect might be more pharmacological 
than just a difference in route of administration. The later onset of 
rimonabant might be caused by the fact that citalopram-induced 5-HT levels 
had reached plateau values, implicating that the effect of rimonabant became 
apparent when the levels of 5-HT started to decline. 
 
A similar additive effect of the combination of citalopram and rimonabant as 
shown in this study was reported by Takahashi et al. who showed that 
cannabinoid CB-1 antagonists have an additive effect on certain behavioral 
parameters when administered concomitantly with citalopram or sertraline 
(Takahashi et al., 2008). In that study the combination of sub threshold dose 
of rimonabant and citalopram both decreased immobility time in the forced 
swim test and tail suspension test.  
 
The present results raise the question whether the observed acute interaction 
between the CB-1 receptor and 5-HT uptake inhibition has any clinical 
implications. As stated in the introduction there is comorbidity between 
cannabis use and depression (Kaminer et al., 2007; Rowe et al., 1995; Troisi 
et al., 1998). Therefore, do depressed patients treated with an SSRI limit the 
effect of their treatment by using cannabis? Indeed depressed patients using 
cannabis display poor illness treatment success rates (Raphael et al., 2005). 
Prospective studies of patients with a comorbidity of depression and 
substance abuse, demonstrate that treatment outcomes, such as symptoms 
prevalence, hospitalizations rates, and life-quality factors are worse when 
compared to single disorder patients (Chouljian et al., 1995; Linszen et al., 
1994; Osher et al., 1994; Swofford et al., 1996).  
Finally it is emphasized that this study is based on acute administrations of 
both cannabinoids and citalopram. Chronic treatment would be more 
relevant when comparing to the clinical situation in depression. It cannot be 
excluded that the observed acute effect of SSRI on 5-HT level is relevant to 
the reported anxiety-like responses caused by acute SSRI (Bagdy et al., 
2001), and that cannabinoids may counteract this effect. 
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Summarizing the results of this study, it was shown that acute stimulation 
and blocking of the CB-1 receptor modulates the effect of citalopram on 
extracellular 5-HT levels in the mPFC. Extrapolating this observation to 
clinical practice suggests that cannabis use might lower the anti-depressive 
effect of an SSRI. This interaction of CB-1 (de)activation and SSRI 
effectiveness might be relevant, since a large percentage of depressed 
patient’s uses cannabis. It is of great importance to study these observations 
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Abstract 
Endocannabinoids (ECs) are lipophilic compounds and are transported 
through the polar environment with the help of chaperone molecules. These 
characteristics affect the recovery rates of microdialysis probes and 
complicate the sampling and quantitation of ECs. To optimize the 
microdialysis setup we have studied the effect of four different 
microdialysis probes combined with three different perfusate additives on 
the in vitro recovery rates of ECs. The results show that adding β-
cyclodextrines (β-CDs) to the perfusate is the most effective way of to 
increase the EC in vitro recovery rate. Other additives were not effective in 
increasing EC recovery rates. The Brainlink-NO probe appeared to be the 
best choice since it realizes the highest recovery rates combined with only a 
minor effect on fluid recovery.  
To minimize tissue damage caused by ultra-filtration or excessive drainage 
due to increased fluid recovery we optimized the (β-CDs) concentration. We 
emphasize to use 2% of β-CDs as this concentration had no effect on fluid 
recovery. In this study we identified the Brainlink-NO probe in combination 




Since its development in the early 1980s in vivo microdialysis is extensively 
used as a in vivo sampling technique of brain tissue. Since microdialysis 
uses a virtually closed system, it results in minimal tissue disturbance during 
sample collection. Samples can be continuously taken and since they 
originate from the extracellular space they resemble relevant physiological 
concentrations much better than those provided after post-mortem brain 
tissue analysis. Samples collected during microdialysis have a low need for 
pre-analytical sample preparation since the membrane acts as a filtering 
barrier against large molecules like enzymes that could degrade the 
constituents.  
Microdialysis is most often used for sampling polar neurotransmitters (e.g. 
monoamines, acetylcholine and amino acids) that easily diffuse though the 
membrane into the lumen of the probe. However, more recently the focus 
for sampling larger and more hydrophobic like ECs, has increased. However 
for proper detection of ECs modifications of the microdialysis 
circumstances are needed 
The cannabinoid system has been the focus of a large number of studies and 
the role of ECs has shown to be extremely diverse. Surprisingly, to the best 
of the authors knowledge there are only 9 experimental reports and one 
review (Buczynski and Parsons, 2010) of in vivo rat microdialysis of ECs, 
derived from four different research groups. Some studies focused on 
fundamental principles of EC signaling (Bequet et al., 2007; Giuffrida et al., 
1999), others studied the role of ECs in pain (Walker et al., 1999) or other 
disease-states (Villanueva et al., 2009). Several EC microdialysis studies 
were directed to the role of ECs on effects induced by drugs of abuse 
(Alvarez-Jaimes et al., 2009; Caille et al., 2007; Ferrer et al., 2007; Orio et 
al., 2009). Despite small variations in methodology such as sampling 
conditions, brain areas and analytical procedures, baseline EC concentration 
across these studies were consistent for both AEA and 2-AG (low 
nanomolars), with 2-AG showing higher (2-8x higher) concentrations.  
 
The efficiency by which an analyte is sampled through the membrane is 
described by the term recovery. Recovery is influenced by factors like the 
flow rate and composition of the perfusate, type of membrane (material and 
pore-size), and the tissues response to probe placement (biofouling). The 
term recovery can be divided into “absolute recovery” (e.g. the mass of 
 101 
analyte collected per unit of time) and “relative recovery” (concentration in 
% related to the concentration of the sampled extracellular fluid). The 
absolute recovery of an analyte is directly proportional to the perfusate flow 
rate (Wages et al., 1986). The first report of EC sampling that studied the 
recovery used a flow rate of 10µl/min (Giuffrida et al., 1999). This study 
lower flow rates resulted in EC levels below the limit of detection (LOD). 
However high flow rates, such as 10µl/min, create a lot of internal probe 
pressure and might affect the extracellular equilibrium (Dykstra et al., 
1992). Most authors agree that flow rates ranging from 0.6-2.0µl/min are 
preferred. The disadvantage of slower flow rates is that they result in smaller 
sample sizes which might put the analytical method under significant strain. 
Another factor influencing the microdialysis recovery of an analyte is the 
membrane type. There is a wide variety in membrane materials, such as 
polyacrylonitrile, regenerated cellulose, polycarbonate, and polysulfone. For 
endocannabinoids the most often used membrane is made of 
polyethylsulfone (PES), which typically has a large pore size of 6-40 kDa, 
and a low EC adsorption (Bequet et al., 2007). ECs are smaller than 1 kDa 
and should be easily sampled using the low molecular weight cut-off 
membranes. However, the fact that ECs might bind to carrier proteins might 
seriously hamper the recovery. To sample carried-bound EC, membranes 
with a molecular cut-off >67kDa (size of albumin)] might be helpful.  
The major factor that determines the EC recovery is probably the perfusate 
composition. ECs are lipophilic and as a consequence will show poor 
solubility when a polar perfusion fluid is used. This poor solubility will 
affect the passage of ECs through the membrane.  
Therefore, the majority of microdialysis studies that sample ECs used an 
additive in the perfusion fluid, namely β-CDs. Because β-CDs have a 
hydrophilic outer surface and a hydrophobic central cavity, this additive can 
form inclusion complexes with non-polar molecules (Schneiderman and 
Stalcup, 2000) like ECs. Including relative high concentrations of β-CDs (up 
to 30%) in the perfusate, has shown to result in a 10-fold increase in 
recovery (Walker et al., 1999). Additionally, β-CDs might reduce the 
adsorption of ECs to the inner wall of the probe and tubing (Bequet et al., 
2007), and lower the concentration of free ECs in the lumen of the probe 
which creates a concentration gradient increasing EC recovery (Khramov 
and Stenken, 1999). When using an additive there is a risk that the 
compound diffuses to the tissue directly surrounding the probe. 
Cyclodextrines can seriously damage cell functioning by extracting 
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cholesterol from plasma membranes (Bari et al., 2005; Ohvo and Slotte, 
1996). 
To reduce tissue damage or toxical effects induced by cyclodextrines, 
alternative additives should be considered.   
Other additives that are often used to increase recovery of lipophilic 
compounds are bovine serum albumin (BSA) (Jensen et al., 2007; Trickler 
and Miller, 2003) or dextran (60-1250kDa) (Dahlin et al., 2010; 
Rosenbloom et al., 2006). The advantage of these additives, when compared 
to β-CDs, is that they are already effective in relatively low concentrations 
(0.02-2%). Using lower concentrations of additives will result in a smaller 
effect on the osmolality of the perfusate, which creates less disturbance of 
the extracellular equilibrium. In addition, lower additive concentrations 
create less ion suppression during MS detection, creating less strain on the 
analytical method. 
 
In the literature there is a wide range of methods used to analyze ECs from 
biological matrixes. Most of them use chromatographic separation. 
Although there are also studies that show chemical derivatization of ECs 
followed by UV spectroscopy (Arai 2000, Yagen 2000, Wang 2001), this 
mechanism suffers from unspecific binding of the derivatization agent.  
Most methods use a combination of either mass-spectrometry coupled to gas 
chromatography (GC-MS) or liquid chromatography (LC-MS). Both of 
these methods produce limits of detection in the low nanomolar range 
(Hardison 2006, Alvarez-Jaimes L. 2009). Using LC coupled to mass 
spectrometry set on single ion monitoring (SIM) has proven to be a reliable 
method for EC quantitation. However, using tandem mass spectrometers 
creates a significant increase in selectivity since both the ion and one of its 
fragmented products can be monitored (multiple reaction monitoring: 
MRM).  
As previously stated, high concentrations of cyclodextrines could induce 
ion-suppression and therefore negatively affect the quantitation of ECs. As a 
consequent, it is recommended to first determine its effects on the analytical 
method, before using this or an alternative additive to enhance recovery. 
 
The goal of this study was to determine the optimal membrane and perfusate 
composition to sample endogenous cannabinoids (anandamide (AEA), 2-
arachidonoylglycerol (2-AG), palmitoylethanolamide (PEA), and 
oleoylethanolamide (OEA)). In order to achieve this we have chosen four 
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types of microdialysis probes that differ in both membrane and probe 
design. Furthermore, we have compared three different types of additives in 
the perfusion fluid in order to determine which combination results in the 
most efficient EC sampling. The primary focus of this study was to identify 
the optimal microdialysis conditions and therefore the experimental setup 
consisted of relatively small group sizes (n≈5). 
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Material and Methods 
 
In vitro microdialysis 
In this study we have used four different types of probes, which were 
equipped with three different membrane types (table 1). For all experiments 
the (total) flow-rate was set at 0.6 µl/min (CMA402 syringe-pump, CMA 
microdialysis). For the MetaQuant (MQ)- probe (Brainlink, The 
Netherlands) we used 0.5 µl/min dilution-flow and 0.1 µl/min ultraslow-
flow. To limit ultrafiltration and therefore loss of perfusion fluid with the 
OM-probe (Brainlink, The Netherlands), the collectors were placed lower 
(40-60cm) than the probe to create a gravity driven pulling force (as 
described by (Rosenbloom et al., 2006)). All probes had an active 
membrane length of 4 mm. Ringers solution (in mM: NaCl 140.0, KCl 4.0, 
CaCl2 1.2, MgCl2 1.0) was used as standard pefusate. We have chosen three 
different additives in multiple concentrations to enhance EC recovery: β-CD 
(1-2-5-10-15-20-30%), BSA (0.2%), and Dextran 60kDa (1-2-5-10-15%).  
 
Table 1: Overview of the different probe characteristics used in this study 
           Probe type           Membrane Material          Cut-off (kDa) 
             MAB 6              Polyethersulfon                   15 
             NO              Polyacrylonitril                40-50 
             MQ              Polyacrylonitril                 40-50 
             OM             Polyethylene                 3000 
 
During in vitro experiment the probes were connected with PEEK tubing 
and first stabilized for two-hours in Ringers solution, after which they were 
placed in EC bath solution and four 30 minute samples were taken using a 
fraction collector (Univentor820 microsampler, TSE systems). The EC bath 
solution consisted of 10-8 M AEA, PEA, OEA, and 10-7 M 2-AG in Ringers 
solution with 0.2% BSA (to prevent non-specific binding of ECs to the inner 
wall of the vial) and 0.02M formic acid (FA) (preventing degradation). The 
stock solution was stirred and kept on 37˚C during the experiment. The 
100% reference sample (bath concentration) was taken at the end of the 
experiment to correct for possible degradation. 
 
Analysis 
EC in vitro recoveries were analyzed using LC-MS/MS. AEA, 2-AG, PEA, 
and OEA (deuterated versions as internal standards) were injected in 
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samples of 18µl into the HPLC-MS/MS system by an automated, and cooled 
samples injector (SIL-20 AC, Shimadzu, Japan). Components were 
separated using a phenyl column (Inertsil Ph-3 (2.1x100 mm, 3 µm 
particles) GC sciences, Japan) perfused with a linear gradient of acetonitril 
(ACN) in UP (table 2). The gradient consisted of solvent A (UP/ACN 0.2 
/99.8 with 0.1% FA) and solvent B (UP/ACN 10/90 with 0.1% FA), and the 
runtime/sample was approximately 7 minutes. All dilutions were prepared in 
0.2% BSA in Ringers solution to prevent non-specific adsorption. 
Calibrations were conducted daily (linear range: 20pM to 20nM). 
 
Table 2: LC scheme ACN 
                          Gradient 
          Time (min)            %B         Valve 
                0.0             30            
                3.0                         MS 
                4.0            100           
                5.0            100            
                6.0              30            
                7.0                      Waste 
                7.01                          Stop 
 
 
MS analysis was performed using an API 5000 MS/MS system consisting of 
an API 5000 MS/MS detector and a Turbo Ion Spray interface, probe 
temperature set at 500 ˚C. The acquisitions were performed in positive 
mode. The instrument was operated in multiple-reaction-monitoring (MRM) 
mode (see table 3 for MRM settings). Data were calibrated and quantified 
using Analyst data system (Applied Biosystem, version 1.4.2.). 
  
Table 3: MS/MS MRM settings 
          Analyte           Q1           Q3 
           2-AG         379.2         287.3 
           AEA          348.2          62.2 
           PEA          300.3          62.2 





Data analysis  
Data are presented as percentage of bath concentration. All data are 
expressed as mean ± SEM. Because of the small group sizes (n=3-5) there 
was no statistical analysis performed for the comparison of additives within 
probe types.  
For effect of additive on fluid recovery the statistical analysis between 
groups was performed with a one-way analysis of variance for repeated 
measures (ANOVA), followed by Student Newman Keuls post-hoc analysis. 
The overall level of significance was set at p < 0.05. 
 
 107 
Results & Discussion 
 
To determine the optimal conditions for sampling endocannabinoids we 
have studied the role of the composition of the perfusion fluid and the 
membrane material on in vitro recovery rates.  
 
 
Figure 1: The effect of four different pefusate compositions (blank Ringer, Ringer-BSA, 
Ringer-Dextran 60kDa, and Ringer-β-CD) on the recovery rate of endocannabinoids using 
4 different probe types: Microbiotech 6 (MAB6), Brainlink-NO (NO), Brainlink-
MetaQuant (MQ), and the Brainlink-openmembrane probe (OM) (n=3-5).  
 
 
Direct comparison of the perfusate compositions and probe types (figure 1) 
shows that adding β-CDs to the perfusion fluid had the highest effect on EC 
recovery. For all four probe types β-CDs increased EC recovery to rates 
ranging from 40% ± 22.4 SEM to 112% ± 41.7 SEM for the NO-probe to a 
maximum recovery ranging from 299% ± 28.4 SEM to 611% ± 105.2 SEM 
for the MQ-probe. Using 0.2% BSA had no effect on EC recovery rates and 
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was as ineffective as the control group of probes perfused with blank 
Ringer.  
Adding 2% Dextran 60kDa was only effective when used in combination 
with the NO-probe. In this approach 2% Dextran 60kDa increased EC 
recovery to rates ranging from 17% ± 8.6 SEM for AEA to 73% ± 37.4 
SEM for PEA. 
Overall AEA showed the lowest recovery and PEA showed the highest 
recovery rates especially when sampled through a MQ-probe, which 
resulted in 30.9% ± 4.7 compared with blank Ringer and to 611% ± 105.2 
SEM using 30% β-CD. 
 
These results clearly indicate that cyclodextrines are the most advantageous 
addition to increase the in vitro recovery of ECs. Where using blank Ringer 
and 0.2% BSA resulted in (average) recovery rates lower than 5%, but 
including 30% β-CDs often resulted in >100% recovery. Although recovery 
rates higher than 100% are suggesting either active carriage over the 
membrane or an increased fluid recovery, both of which could result in 
adverse effects in vivo, these results clearly confirm the earlier postulated 
notion that β-CDs are an effective tool in increasing EC microdialysis 
recovery (Buczynski and Parsons, 2010). The ineffectiveness of BSA as a 
perfusate additive in increasing EC levels was unexpected. BSA has proven 
to prevent fluid loss (ultra filtration), when used as a perfusion additive in 
microdialysis, and is therefore expected to increase recovery rates (Trickler 
and Miller, 2003). Another mechanism by which BSA could increase 
recovery of lipophilic compounds like ECs is that it will bind to the 
lipophilic binding sites  in the lumen of the probe, both at the membrane site 
and tubing, so that ECs will stay in solution when transported to the 
collection vial (Jensen et al., 2007). A Third hypothesis by which BSA 
could aid recovery of large or lipophilic compounds is by binding to the 
lipophilic compound and thereby facilitating transport of these compounds 
to the probe and through the tubing. The ineffectiveness of BSA in the 
present study might be explained by the relatively low concentration that 
was used. Another possible explanation is that BSA bound too strong ECs  
keeping the compounds  in solution both during the experiment and 
analysis. The analytical method was designed to prevent entry of BSA into 
the MS/MS, which could cause contamination, damage, and ion 
suppression, and therefore the eluens was switched to waste the first 3 
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minutes. ECs bound to BSA might consequently not have reached the 
MS/MS. 
Dextran has proven to be a useful additive in microdialysis studies by 
increasing the recovery of large lipophilic molecules, by preventing fluid 
loss like BSA (Rosenbloom et al., 2006). In that study, Dextran 70kDa 6% 
increased the absolute recovery while actually lowering the relative recovery 
of proteins. In the present study Dextran only showed to be effective in 
combination with the NO-probe, where it increased recovery to 17.1% for 
AEA to 73.1% for PEA. These results were unexpected since the beneficial 
effect of adding Dextran should be mainly present in combination with a 
large pore membrane, where Dextran could increase recovery by preventing 
fluid-loss. 
 
In all four probe and membranes types adding β-CDs to the perfusate 
resulted in the highest recovery rates, some even higher than the optimal 
100%. Since including a relatively high concentration of β-CDs will affect 
the osmotic balance, which will result in an inward movement of fluid into 
the perfusion fluid in order to correct for the difference in osmolality on 
both sides of the membrane. Although the scale of the excessive fluid 
recovery will determine the effect it has in vivo, tissue drainage of extra 
cellular fluid and constituents might induce pathological events. Therefore 
in the present study the amount of fluid recovered was carefully monitored 
(figure 2).  
The MAB6 probes recovered the highest amount of fluid with a fluid 
recovery of 164% ± 5.4 SEM (n=4), while the MQ-probes recovered the 
lowest amount of extra fluid with 110% ± 1.4 SEM (n=4). The NO- and 
OM-probe in combination with 30% β-CDs recovered fluid amounts of 




Figure 2: The effect of 30% β-CDs on the fluid recovery of four different 
probe types. The area in red resembles the excess of fluid recovered.  
 
There seems to be a relation between flow-speed at the membrane and the 
amount of fluid recovery when using 30% β-CDs. The probes with the 
highest internal diameter (the MAB6: ID ± 0.48mm and OM-probe: ID 
0.33mm) that consequently have the lowest flow-speed at the membrane, 
displayed the highest fluid recovery. Although the MQ-probe has an even 
lower speed at the membrane with only one sixth of the total flow passing at 
the membrane, the absolute fluid recovery is lower than the other probes. 
When correcting for the lower membrane flow in the MQ-probe the fluid 
recovery increases from 110% to 160%, which is similar to the MAB6 
probe. With the settings applied in the present study, the NO-probe suffers 
the lowest amount of β-CD induced ultra-filtration. 
Surprisingly, none of the studies previously reported and discussed the 
increase in fluid recovery when using β-CDs. Cyclodextrines are able to 
extract cholesterol from plasma membranes (Ohvo and Slotte, 1996) which 
results in a disruption of the lipid raft integrity (Bari et al., 2005; Ohvo and 
Slotte, 1996). Since this lipid membrane controls the CB1 receptor binding 
and signaling (Bari et al., 2005) any direct tissue contact of cyclodextrines 
might affect EC levels. However, Rosenbloom et al showed that an increase 
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in vitro fluid recovery not directly implies that in vivo the fluid recovery is 
also affected (Rosenbloom et al., 2006). The latter study showed that adding 
Dextran 70 kDa 6% to the perfusion fluid resulted in an increase in in vitro 
fluid recovery to more than 180%. Under the same conditions in vivo only a 
minor increase in fluid recovery to 110% was observed. This difference 
between in vitro and in vivo effects could mean that monitoring in vitro fluid 
recovery is not a relevant measure controlling in vivo ultra-filtration. 
 
To establish the optimal cyclodextrine concentration six lower 
concentrations of β-CDs were used in combination with a NO-probe (figure 
3). Without adding β-CDs the recovery is virtually absent (EC recovery < 
5%), while adding 30% β-CDs resulted in recoveries higher than 100%. 
Figure 3 shows a dose-response of β-CDs on the recovery of ECs. Adding 
2% or 5% was as effective as 10% and resulted in recovery rates ranging 
from 15.2% for AEA to 52.5% for PEA. 
 
 
Figure 3: The effect of β-CDs (0-30%) on the recovery rate of 
endocannabinoids using a NO-probe.  
 
In the present study addition of β-CDs 30% resulted in recovery rates 
ranging from 40 to more than 600% (figure 1). These recovery rates are 
higher than the 5.09-5.90% range initially reported in the first study 
conducting EC microdialysis (Walker et al., 1999). In that study a low 
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recovery of about 0.34% using blank perfusate was reported, which is 
similar to the average recovery rate of 1.19% found in the present study. 
Reviewing the difficulties of sampling ECs Buczynski et al, showed that 10, 
20 and 30% β-CDs are similar in effectiveness and realized a recovery rate 
of around 4% for AEA and 8% for 2-AG (Buczynski and Parsons, 2010). To 
the author’s opinion, the difference in recovery rate between the results of 
the present study and those reported in literature is difficult to explain by the 
methodological differences (perfusion fluid: Ringer vs. aCSF; connective 
tubing: PEEK vs. FEB) between our and their experimental setup. The most 
feasible factor responsible for the differences between the current results 
and those of Walker et al and Buczunski et al is the type of dialysis 
membrane used.  
 
The results of the fluid recoveries of different concentrations of β-CDs show 
a dose-response relation and are presented in figure 4. Increasing the 
concentration of β-CDs above 5% resulted in fluid recoveries higher than 
100%, which were significantly different from 15% and higher 
concentrations (F(7,27)=9.021, p<0.001). 
 
 
Figure 4: The effect of different concentrations of β-CDs (0-30%) on the 
fluid recovery of during collection using a Brainlink-NO probe. * p<0.01 
relative to 0% β-CDs. 
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Considering the pathological effects we observed during in vivo experiments 
(incidentally inducing paralysis; unpublished observations) using high 
concentrations of β-CDs in the perfusion fluid, all measures should be taken 
to prevent ultrafiltration and fluid drainage from the extracellular space. 
Therefore the optimal sampling conditions are not primarily those based on 
the highest possible relative recovery rates. The optimal sampling conditions 
are rather a balance between relative EC recovery and fluid recovery. Based 
on our results it is concluded that a β-CD concentration of 2% is conjunction 
with a NO-probe is the optimal sampling condition. Using these conditions 
we were able to sample and quantify ECs in in vivo experiments without 





The fact that only four laboratories were able to sample ECs from freely 
moving animals, using microdialysis, might be related to difficulties in 
controlling the recovery rate of these compounds. In the present study the 
optimal conditions for sampling ECs were determined. It was found that that 
a β-CD concentration of 2% is conjuction with a NO-probe is the optimal 
sampling condition. By applying these conditions an excess of fluid 
recovery was prevented and an acceptable recovery of the ECs for in vivo 
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The role of endocannabinoids (ECs) in the reward circuit has recently been 
the subject of various studies. It is generally assumed that ECs play a 
regulatory role regarding the reward-induced dopamine (DA) release in the 
NAc shell. Since extracellular ECs are difficult to sample, because of their 
lipophilic properties, microdialysis studies aimed at the pharmacology of the 
ECs are scarce. Here we studied the effects of nicotine on extracellular ECs 
and dopamine (DA) in the nucleus accumbens (NAc). Two microdialysis 
probes were implanted in the ventral tegmental area (VTA) and the 
ipsilateral NAc respectively. Nicotine was administered systemically or by 
local infusion through the microdialysis probes, whereas the extracellular 
levels of ECs (AEA, 2-AG, OEA, PEA) as well as DA were monitored in 
the VTA and NAc. To further evaluate the role of the CB-1 receptor in 
nicotine induced reward processes the CB-1 antagonist rimonabant was co-
administered with nicotine. A LC-MS/MS method was used to analyze the 
ECs and DA in the dialysis samples. 
The results of this study showed that administration of nicotine 
(systemically as well as locally) enhanced DA release in the NAc shell. The 
increase of DA release in the NAc shell after local infusion of nicotine was 
dose-dependently inhibited by rimonabant, confirming the modulating role 
of the cannabinoid system in reward. Furthermore, while systemic nicotine 
increased the levels of all four ECs, the increase in AEA and OEA were 
inhibited by rimonabant. This indicates that AEA and OEA are implicated in 
the modulation of nicotine reward processes. Further evaluation of the 






Tobacco use by cigarette smoking is known to lead to serious health issues, 
such as various forms of cancer, pulmonary and cardiac diseases. Nicotine 
has been recognized to be the main addictive component of tobacco smoke, 
(Stolerman and Jarvis, 1995).  
Although clinical and pre-clinical studies indicate that several 
neurotransmitter systems mediate the neurobiological effects underlying 
nicotine addiction (George and O'Malley, 2004; Tanda and Goldberg, 2000), 
dopamine (DA) in the mesolimbic system is regarded as a crucial factor 
mediating the rewarding effects of drugs of abuse, including nicotine (Di 
Chiara and Imperato, 1988). While DA release in the nucleus accumbens 
(NAc) shell received much attention, focus of research has recently shifted 
towards systems that modulate the release of DA, like the endocannabinoid 
and opioid systems (reviewed by (Maldonado and Berrendero, 2010)). 
The distribution of CB-1 receptors in the CNS has been studied extensively 
(Herkenham, 1992; Herkenham et al., 1990; Moldrich and Wenger, 2000; 
Tsou et al., 1998). CB-1 receptors are found all over the brain and in 
significant densities in both the NAc and the VTA (Wenger et al., 2003). 
Furthermore, CB-1 receptors are known to co-localize with other receptor 
types, like opioid receptors (Salio et al., 2001).  
A large body of evidence demonstrates that the endocannabinoid system is 
involved in nicotine-induced reward processes (Maldonado et al., 2006; 
Scherma et al., 2008a). Three different cannabinoid CB-1 receptor 
antagonists (rimonabant, AM251, and SLV330) have been shown to 
effectively decrease nicotine self-administration in rats (Cohen et al., 2002; 
de Bruin et al., 2011; Shoaib, 2008). Furthermore, nicotine has been shown 
to induce conditioned place preference (Le Foll and Goldberg, 2005), 
indicating the addictive potential of nicotine, which both in rat and mice, has 
shown to partially depend on CB-1 receptors (Biala et al., 2009; Budzynska 
et al., 2009; De Vries et al., 2005; Le Foll and Goldberg, 2004; Merritt et al., 
2008). The possibility of nicotine receptors and CB-1 receptors co-
localizing within the NAc and/or VTA might suggest a role (direct or 
indirect) of CB-1 receptors in nicotine induced reward processes.  
Monitoring extracellular DA levels with microdialysis or voltammetry 
showed that the nicotine-induced effects on DA in the NAc shell are 
blocked by rimonabant pretreatment (Cheer et al., 2007; Cohen et al., 2002). 
In addition, rimonabant was also found to block the nicotine-induced effects 
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on DA in the NAc shell and in the bed nucleus of the stria terminalis (Cohen 
et al., 2002), a structure connected with both the NAc and ventral tegmental 
area (VTA) and critical for the acquisition and maintenance of drug 
addiction (Epping-Jordan et al., 1998; Erb and Stewart, 1999). 
In humans, rimonabant has shown potential as an antirelapse agent in 
nicotine-addiction and obesitas. Nicotine addicts displayed significantly 
higher quitting rates when using rimonabant compared to placebo-treated 
smokers (Cahill and Ussher, 2007; Fernandez and Allison, 2004).  
 
Rats chronically treated with nicotine showed higher anandamide (AEA) 
tissue content levels in the limbic forebrain, a region important in reward 
processes (Gonzalez et al., 2002). By contrast, in the hippocampus, striatum, 
and cerebral cortex chronic nicotine treatment actually decreased both AEA 
and 2-arachidonoylglycerol (2-AG) levels, whereas CB-1 receptor mRNA 
levels remained unaffected. Furthermore, blocking the enzymatic 
degradation of AEA by administration of URB597 prevented the 
development of nicotine induced conditioned place preference (CPP), and 
acquisition of nicotine self-administration (Scherma et al., 2008b). It is 
assumed that increased synaptic AEA following administration of URB597 
reduced the nicotine-induced enhanced DA release in the NAc shell, 
probably through inhibition of glutamate release in the VTA. Similar 
inhibitory effects on nicotine-induced DA release in the NAc shell were 
observed by two other ECs: oleoylethanolamide (OEA) and 
palmitoylethanolamide (PEA) (Melis et al., 2008). Using 
electrophysiological methods Melis et al showed that OEA and PEA 
blocked the effects of nicotine by activation of the peroxisome proliferator-
activated receptor-α (PPAR-α), a nuclear receptor transcription factor 
involved in aspects of energy management. Ultimately the activation of 
PPAR-α was hypothesized to lead to a negative regulation of neuronal 
nicotinic acetylcholine receptors. 
 
While nicotine affects DA release both in the VTA and NAc shell (Kleijn et 
al., 2011b), the role of ECs within these regions during systemic or local 
nicotine administration remains to be determined. In an earlier study we 
hypothesized that the nicotine-induced DA release is modulated in the NAc 
shell rather than in the VTA. In the present microdialysis study we 
investigated the role of extracellular ECs in the nicotine-induced DA release 
in the VTA-NAc shell pathway. An LC-MS-MS method was developed to 
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determine the ECs in dialysates. Microdialysis probes were implanted in 
both the NAc shell and VTA and samples were collected during nicotine 
administration (both systemic and local through the microdialysis probe).  In 
addition the effect of rimonabant on the neurochemical effects of nicotine 
were determined. Microdialysis samples were analyzed for DA and the ECs: 
AEA, 2-AG, PEA, and OEA. 
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Material and Methods 
 
Animals  
Male Sprague-Dawley rats (275-320g; Harlan, The Netherlands) were used. 
After surgery, animals were individually housed in plastic cages 
(35x35x40cm). Food (Harlan Teklad Global Diet, Blackthorn, UK) and 
water was available ad libitum throughout the entire experiment. The 
experiments were conducted during the light phase (07:00h – 19:00h) in a 
temperature (22 ± 2 ˚C) and humidity (55 ± 10 %) controlled room. 
Experiments were approved by the committee for animal experimentation of 
the University of Groningen. 
 
Drugs and drug treatment 
The CB-1 antagonist rimonabant (Kemprotec limited, Middlesbrough UK) 
was dissolved as previously described (Kleijn et al., 2011a) in a mixture of 
1% TWEEN80 and sterile saline. Nicotine-di-tartrate purchased from 
Sigma-Aldrich, was dissolved in either saline for systemic injections, or in 
Ringer’s solution for infusion via retrograde microdialysis into the VTA or 
NAcc shell. Solutions were brought to pH 7 using sodium hydroxide. After 
preparation on the day of experiment, solutions of nicotine and rimonabant 
were injected sub-cutaneously (s.c.) in a volume of 1 ml/kg bodyweight or 
infused locally in concentrations ranging from 1 to 100 µM. 
 
Surgery and in vivo microdialysis 
Two microdialysis probes were implanted simultaneously in each rat: one 
probe in the NAc and one in the VTA. Both microdialysis probes were 
implanted under isoflurane anesthesia (2.5%, 0.6l/min O2). Local analgesia 
was applied with bupivacaine, and finadyne (2mg/kg, 1ml/kg s.c.) and was 
given for general peri- and post-operative analgesia. For the NAc shell 
(coordinates: A/P 2.0, L/M 1.2, V/D -7.9) and VTA (coordinates: A/P -5.0, 
L/M 0.9, V/D -8.2) 9 mm long I-shaped microdialysis probes were 
implanted (1.5 mm exposed membrane; polyacrylonitril, MW cut-off 40-50 
kDa; Brainlink, the Netherlands). After surgery animals were allowed to 
recover for 24 h. Animals were randomly distributed between dose groups.  
 
Microdialysis experiments were carried out by perfusing the probes with 
Ringer’s solution (in mM: NaCl 142.0, KCl 3.0, CaCl2 1.2, MgCl2 1.2) at a 
flow rate of 1.5 µl/min (CMA402 syringe-pump, CMA microdialysis). For 
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sampling ECs β-cyclodextrin 2% was added to the Ringers solution and the 
flow rate was adjusted to 0.6µl/min, both changes incorporated to increase 
analyte recovery (see chapter 5). Twenty minute samples were collected 
using a fraction collector (Univentor 820 microsampler, TSE systems) and 
samples were stored at -80 oC until analysis. The experiment started with the 
collection of four base-line samples during which at t = -30 min an 
administration of rimonabant (1 or 3 mg/kg) was given. At t = 0 min 
nicotine or vehicle was administrated, either systemically (0.5 mg/kg s.c. 
(nicotine salt)) or locally [NAc: 1 µM, and VTA: 100 µM (both 
concentrations determined to be the lowest effective dose in earlier studies 
(Kleijn et al., 2011b))] and the effect of the drug interaction on DA and EC 
release was monitored for 3 hours. At the end of the experiment, the animals 
were euthanized using an overdose of pentobarbital (20 %) and probe 
placement was histologically evaluated. 
 
DA analysis 
Dialysate DA content was determined by an LC-MS/MS method as 
previously described (Rollema et al., 2011) using a Shimadzu LC-10-ADvp 
system connected to a Sciex API 4000 MS/MS unit (Applied Biosystems, 
the Netherlands). Chromatographic separation was performed using a 
reversed phase Synergi MAX-RP 100 x 3 (2.5 µm particle size) column. 
After a soft ionization moiety derivatization, DA levels were analyzed in the 
MS/MS with high sensitivity (LOQ: 0.05 nM) and selectivity. Data 
acquisition and analysis was performed using Analyst® 1.4.2. 
 
EC analysis 
AEA, 2-AG, PEA, and OEA (deuterated versions as internal standards) were 
injected in samples of 20µl into the HPLC-MS/MS system by an automated, 
and cooled samples injector (SIL-20 AC, Shimadzu, Japan). Components 
were separated using a phenyl column (Inertsil Ph-3 (2.1x100 mm, 3 µm 
particles) GC sciences, Japan) perfused with a linear gradient of acetonitril 
(ACN) in UP (Table 1). The gradient consisted of solvent A (UP/ACN 0.2 
/99.7 with 0.1% formic acid (FA)) and solvent B (UP/ACN 10/90 with 0.1% 
FA). All dilutions were made with 0.2% BSA in Ringers solution to prevent 
non-specific adsorption.  
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MS analysis was performed using an API 5000 MS/MS system consisting of 
an API 5000 MS/MS detector and a Turbo Ion Spray interface, probe 
temperature set at 500 ˚C. The acquisitions were performed in positive 
ionization mode. The instrument was operated in multiple-reaction-
monitoring (MRM) mode (see Table 2 for MRM settings). Data acquisition 
and analysis was performed using Analyst® 1.4.2. 
  
Table 2: MS/MS MRM settings 
          Analyte          Q1           Q3 
           2-AG         379.2          287.3 
           AEA          348.2           62.2 
           PEA          300.3           62.2 




For baseline samples (t = -60 to 0 min) of each drug treatment group were 
per brain region submitted to a one-way analysis of variance (ANOVA) for 
repeated measures with drug dose as between subjects factor, to exclude 
possible group differences. Subsequently, microdialysis data were expressed 
as percentages of mean baseline within each subject.  
To evaluate the effect of drug (nicotine, rimonabant) treatment on DA and 
EC levels, statistical analysis was performed per analyte per brain region 
with a two-way repeated measure ANOVA, testing for the effect of 
treatment and time, followed by Student Newman Keuls post-hoc analyses. 
The overall the level of significance was set at p<0.05. 
 
                           Gradient 
   Time (min)            %B          Valve 
               0.0             30         
               3.0                          MS 
               4.0            100             
               5.0            100              
               6.0          30          
               7.0          Waste 




The effects of administration of rimonabant (1 or 3 mg/kg s.c) on DA and 
EC release enhanced by acute nicotine administration by systemic 
application (0.5 mg/kg s.c.) or local infusion (100 µM infused into the VTA 
or and 1µM infused into the NAc shell) were assessed by in vivo 
microdialysis of the VTA and the NAc shell.  
 
Basal values 
There were no significant differences between baseline values of the various 
experimental groups for extracellular DA or any of the extracellular ECs (2-
AG, AEA, OEA or PEA) both in the VTA and NAc shell. The baseline 
neurotransmitter levels per brain region are presented in Table 3. When EC 
levels in the VTA and the NAc shell were compared, only PEA was present 
in significantly higher levels in the VTA (F(1,58)= 9.885; p=0.003) (*). 
 
Table 3: Mean basal neurotransmitter levels in brain dialysates (not corrected for recovery) 
             Monoamine              Brain area            Concentration (nM) 
                           (± SEM)  
               n = 
            (total study) 
                 F-value  
             (treatment-effect) 
                Dopamine              NAC shell                   2.09 ± 0.31                   93               F(18,74)= 0.919; N.S. 
                   2-AG               VTA                   1.64 ± 0.40               59               F(9,43)= 1.239; N.S. 
               NAC shell                  0.99 ± 0.19                   61               F(9,45)= 1.370; N.S. 
                   AEA               VTA                   0.10 ± 0.02                  59               F(9,43)= 1.538; N.S. 
              NAC shell                  0.08 ± 0.01                  61               F(9,45)= 1.050; N.S. 
                   OEA               VTA                   3.27 ± 0.30                  59        F(9,43)= 1.88; N.S. 
              NAC shell                  1.97 ± 0.23                  61                F(9,45)= 1.393; N.S. 
                   PEA               VTA                   17.38 ± 2.34 *                 59               F(9,43)= 1.832; N.S. 
              NAC shell                  11.17 ± 0.97                  61               F(9,45)= 1.935; N.S. 
 
*significantly higher basal level compared to the NAc shell 
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Systemically administered nicotine enhanced DA release in the NAc 
shell: effects of rimonabant 
Systemic administration of 0.5 mg/kg (s.c.) nicotine resulted in a significant 
increased in DA release in the NAc shell, to about 160% of baseline (Figure 
1). This increase lasted from 20 to and including 160 minutes after 
administration. Although this nicotine induced DA release was found to be 
significant for both treatment (F(5,267)=6.544; p<0.001), time 
(F(10,267)=11.010; p<0.001) and the interaction of treatment and time 
(F(50,267)=3.506; p<0.001), there was no effect of co-administrating 
rimonabant (1 and 3 mg/kg s.c.) with nicotine. However, there is a tendency 
towards a decrease in nicotine induced DA release following a co-
administration of rimonabant 1 mg/kg s.c. (p=0.067). 
 
 
Figure 1: Effects of rimonabant (1 mg/kg (open circle), 3 mg/kg (closed 
triangle); s.c.) or vehicle (closed circle), administered at t = -30 min, on DA 
release induced by nicotine (0.5 mg/kg; s.c.; administered at t = 0 min) in 
the NAc shell. As control administrations vehicle-vehicle (open triangle), 
rimonabant (1mg/kg s.c.) / vehicle (closed square), and rimonabant (3 
mg/kg s.c.) / vehicle (open square) were included. Data are expressed as 
mean percentages of baseline ± SEM (n = 5-7 per treatment).  
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Local administration of nicotine into the VTA enhanced DA release in 
the NAc: effect of rimonabant 
Local infusions of 100 µM nicotine into the VTA induced a significant 
increase in DA levels within the ipsilateral NAc shell, compared to vehicle 
treatment (F(3,190)=8.957; p=<0.001; Figure 2). Although the increase in DA 
release reached a maximum of about 150 % of baseline 60 min after 
injection, there was no significant effect over time (F(10,190)=0.730; 
p=0.695). Co-administration of rimonabant reduced the effect of VTA 
nicotine infusion significantly, while rimonabant itself had no effect on NAc 
shell DA levels. There was no difference in effectiveness between the two 
doses of rimonabant in reducing nicotine’s effects in DA levels. 
 
 
Figure 2: Effects of s.c. rimonabant, 1 mg/kg (open circles) or 3 mg/kg 
(closed triangles) on DA release in the NAc shell induced by local nicotine 
(100 µM, closed circle) into the VTA. As control administrations vehicle-
vehicle (open triangle), rimonabant (1mg/kg s.c.) and vehicle (closed square), 
and rimonabant (3 mg/kg s.c.) and vehicle (open square) were included. 
Rimonabant was administered at t = -30 min Data are expressed as mean 
percentages of baseline ± SEM (n = 5-7 per treatment).  
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Local administration of nicotine into the NAc enhanced DA release in 
the NAc: effect of rimonabant 
Infusing of nicotine in low doses (1µM) into the NAc shell, while 
simultaneously sampling this region, induced an increase in DA levels to 
about 150% of baseline (Figure 3). The increase in DA levels persisted 
duration the nicotine infusion and was significant from t= 40 to t= 200 
minutes (F(10,177)=2.289; p=0.015). The increase in NAc shell DA levels was 
fully suppressed by co-administration of both doses of rimonabant (1 and 3 
mg/kg s.c.; F(3,177)=6.281; p=0.004). Administration of vehicle or 
rimonabant alone did not affect DA levels within the NAc shell. 
 
 
Figure 3: Effects of rimonabant 1 mg/kg (open circle), 3 mg/kg (closed 
triangle); s.c.), on DA release in the NAc shell induced by local nicotine 
infusion (1µM; starting at t=0 min, closed circles).  As control 
administrations vehicle / vehicle (open triangle), rimonabant (1mg/kg s.c.) / 
vehicle (closed square), and rimonabant (3 mg/kg s.c.) / vehicle (open 
square) were included. Rimonabant was administered at t = -30 min Data 






Effect of systemically administrated nicotine on extracellular EC levels 
in the VTA: effects of rimonabant  
Nicotine (0.5 mg/kg) had a pronounced effect on the extracellular levels of 3 
of the 4 studied ECs (Figure 4) in the VTA. Nicotine increased extracellular 
AEA levels to about 450% compared to baseline (F(11, 316)=10.497; p<0.001; 
post hoc test between t= 60-220 min).  
Nicotine induced an increase in extracellular OEA levels in the VTA. The 
maximum increase was about 550% of baseline, 220 minutes after systemic 
nicotine administration (F(11,318)=35.010; p<0.001; post hoc test between t= 
60-220 min). 
Nicotine also increased PEA levels within the VTA to a maximum of about 
470% of baseline 220 minutes after systemic nicotine administration 
(F(11,310)=55.773; p<0.001; post hoc test between t= 40-220 min).  
Although, systemic administration of nicotine did not significantly affect 
VTA 2-AG levels compared to baseline, there was an effect of treatment and 
in time within this group of animals (treatment: F(5,305)=7.545; p<0.001); 
time: (F(11, 305)=3.907; p<0.001). There was no significant effect of nicotine 
on extracellular 2-AG in the VTA when compared to vehicle treatment, 
although there is a trend to increase its levels (p=0.06). 
 
Figure 4 also shows the effect of rimonabant (1 and 3 mg/kg s.c.) on 
systemic nicotine induced EC release within the VTA. Rimonabant alone 
did not affect EC levels in the VTA compared to the vehicle-vehicle 
treatment. Furthermore, no time dependent change was observed for any of 
the ECs in the vehicle / vehicle group.  
Rimonabant dose-dependently inhibited the nicotine induced increase in 
AEA release (F(5,316)=15.296; p<0.001). While rimonabant 1 mg/kg already 
decreased the effect of nicotine on AEA levels (p=0.042), it was not as 
effective as the higher dose of rimonabant (3 mg/kg), which fully 
suppressed the nicotine-induced AEA increase.  
The nicotine induced increase in OEA was also dose dependently inhibited 
by co-administration of rimonabant (1 and 3 mg/kg s.c.; F(5,318)=12.530; 
p<0.001).  
Co-administration with rimonabant did not affect the nicotine-induced PEA 




Figure 4: Effects of rimonabant (1 mg/kg (open circle), 3 mg/kg (closed triangle); s.c.) or 
vehicle (closed circle), administered at t = -30 min, on nicotine (0.5 mg/kg; s.c.; 
administered at t = 0 min) induced VTA EC release (2-AG: upper left; AEA: upper right; 
OEA: lower left; PEA: lower right). As control administrations vehicle-vehicle (open 
triangle), rimonabant (1mg/kg s.c.) / vehicle (closed square), and rimonabant (3 mg/kg s.c.) 
/ vehicle (open square) were included. Data are expressed as mean percentages of baseline 
± SEM (n = 5-7 per treatment).  
 
 
Effect of systemically administered nicotine on extracellular levels of 
EC in the NAc shell: effect of rimonabant 
Nicotine (0.5 mg/kg) increased the extracellular levels of 2-AG, AEA, OEA 
and PEA in the NAc shell (Figure 5).  
Systemic administration of nicotine significantly increased 2-AG levels in 
the NAc shell to about 250% of controls (F(11, 305)=3.907; p<0.001; post hoc 
test between t= 140-220 min) and vehicle treatment (F(5,288)=3.588; 
p=0.011).  
Nicotine (s.c.) induced a significant increase of AEA levels to 330% of 
baseline (F(11, 320)=25.710; p<0.001; post hoc test for t= 120,160-220 min). 
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OEA levels rose to about 450% of controls after nicotine treatment (F(11, 
320)=25.710; p<0.001; post hoc test between t= 60-220 min), PEA levels 
within the NAc shell region increased to a maximum of about 450% of 
baseline 200 minutes after systemic nicotine administration 
(F(11,319)=64.171; p<0.001; significant post hoc test between t= 40-220 min).  
 
The effect of rimonabant (1 and 3 mg/kg s.c.) on systemic nicotine induced 
EC release within the NAc is also shown in Figure 5. Rimonabant inhibited 
the nicotine induced increase of OEA levels in the NAc shell, while leaving 
the increase in 2-AG, AEA, and PEA levels unaffected. The increase in 
extracellular OEA levels in the NAc shell after nicotine (s.c.) administration 
was dose-dependently inhibited by co-administration of rimonabant (F(5, 
320)=7.524; p<0.001). From t = 100 minutes after nicotine administration the 
effect of rimonabant 3 mg/kg s.c. resulted in a significantly lower NAc shell 
OEA level compared to nicotine treatment alone. 
 
Rimonabant alone did not affect EC levels in the NAc shell compared to the 
vehicle-vehicle treatment. For 2-AG, AEA, and PEA there was no effect in 
time of vehicle-vehicle treatment. However, vehicle-vehicle treatment did 
affect PEA levels within the NAc shell (F(11,319)=64.171; p<0.001; post hoc 




Figure 5: Effects of rimonabant (1 mg/kg (open circle), 3 mg/kg (closed triangle); s.c.) or 
vehicle (closed circle), administered at t = -30 min, on nicotine (0.5 mg/kg; s.c.; 
administered at t = 0 min) induced NAc shell EC release (2-AG: upper left; AEA: upper 
right; OEA: lower left; PEA: lower right). As control administrations vehicle-vehicle (open 
triangle), rimonabant (1mg/kg s.c.) / vehicle (closed square), and rimonabant (3 mg/kg s.c.) 
/ vehicle (open square) were included. Data are expressed as mean percentages of baseline 
± SEM (n = 5-7 per treatment).  
 
 
Effects of local infusion of nicotine into the VTA on extracellular levels 
of EC in the VTA and ipsilateral NAc shell: effects of rimonabant 
Infusion of 100 µM of nicotine into the VTA did not affect 2-AG 
(F(3,186)=2.026; N.S) and AEA (F(3,200)=0.286; N.S) levels (Figure 6). In 
addition, within the NAc shell the levels of 2-AG and AEA were not 
affected by the infusion of nicotine or the vehicle in the VTA.  No effects 
were seen after systemic administration of rimonabant or vehicle (2-AG: 
F(3,200)=0.907; N.S; for AEA: F(3,197)=2.657; N.S). 
Although there were effects over time on the OEA levels and for treatment 
and time on PEA levels, none of them were nicotine dependent. For OEA 
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there was an effect in time in both the VTA (F(11,202)=1.932; p=0.037) and 
NAc shell (F(11,212)=3.384; p<0.001), post-hoc analyses revealed that these 
changes did not occur compared to baseline. 
Although nicotine infusion into the VTA had no effect on EC levels, 
including PEA, administration of vehicle or rimonabant 3 mg/kg did, 
however, affect PEA levels in the VTA (treatment x time: F(33,200)=2.561; 
p<0.001) and the NAc shell (F(3,215)=4.687; p=0.012). Within the VTA, PEA 
levels were increased from t= 80 after rimonabant or t=100 minutes after 
vehicle / vehicle administration and lasted for the duration of the 
experiment. In the NAc shell, PEA levels were increased from t=200 
minutes after rimonabant or t=60 minutes after vehicle / vehicle 





Figure 6: Effects of nicotine infusion (100µM) into the VTA on the release of 
extracellular 2-AG, AEA, OAE and PEA (closed circles) in the VTA and NAc 
shell. In addition the effect of co-administration with rimonabant 3 mg/kg (open 
circle) administered at t = -30 min is shown. As control administrations vehicle / 
vehicle (closed triangle) and rimonabant (3mg/kg s.c.) / vehicle (open triangle) are 
included. Data are expressed as mean percentages of baseline ± SEM (n = 5-7 per 
treatment).  
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Effect of local infusion of nicotine into the NAc shell on extracellular 
levels of EC in the NAc shell and VTA: effects of rimonabant 
Infusion of 1 µM nicotine into the NAc shell did not affect extracellular 
levels of 2-AG in the NAc or VTA (NAc shell: F(3,186)=0.919; N.S; and 
VTA: F(3,194)=0.489; N.S) Even so no effects were seen on AEA levels (NAc 
shell: F(3,186)=1.771; N.S; and VTA: F(3,199)=2.872; N.S) (Figure 7). 
Although infusing nicotine into the NAc shell did not affect OEA and PEA 
levels within the NAc shell or VTA, these ECs were affected by 
administration of vehicle or rimonabant 3 mg/kg. Within the VTA OEA 
increased in animals receiving systemic rimonabant 3 mg/kg (s.c.) compared 
to the other treatment groups (vehicle / vehicle, NAc nicotine infusion 
without and with rimonabant) (F(3,200)= 6,579; p=0.003). The levels of PEA, 
within the NAC shell and the VTA, were increased by the administration of 
both vehicle / vehicle and rimonabant 3 mg/kg (s.c.) alone. In the VTA, 
there was an effect for treatment, time and the interaction of treatment and 
time (F(33,197)=3,729; p<0.001) which lasted from t=100 minutes and t=40 
minutes till the end of experiment for vehicle / vehicle and rimonabant 
3mg/kg, respectively. The levels of PEA increased within the NAc shell 
after rimonabant and vehicle administration, compared to other treatments 
(F(3,206)=6,878; p=0.002), which started at t=60 (vehicle) and t=40 





Figure 7: Effects of nicotine infusion (1µM) into the NAc on the release of extracellular 2-
AG, AEA, OAE and PEA (closed circles) in the VTA and NAc shell. In addition the effect 
of co-administration with rimonabant 3 mg/kg (open circle), administered at t = -30 min, is 
shown. As control administrations vehicle / vehicle (closed triangle) and rimonabant 
(3mg/kg s.c.) / vehicle (open triangle) are included. Data are expressed as mean percentages 






Similar to most other drugs of abuse nicotine has been shown to increase the 
activity of DA neurons in the VTA and consequently enhance DA release in 
the NAc (Cheer et al., 2007; Kleijn et al., 2011b; Nisell et al., 1994a). In the 
present study we have applied the microdialysis technique to investigate 
whether the endocannabinoid system is involved in this nicotine-dopamine 
interaction. To that end the CB-1 antagonist rimonabant was co-
administered with nicotine whereas extracellular DA was recorded both in 
the VTA and NAc shell. In the second part of this study we have 
investigated whether the sampling of extracellular ECs by microdialysis 
could contribute to substantiate a possible nicotine-DA-CB-1 interaction.  
 
The nicotine-induced DA release in the VTA and NAc shell: effect of 
rimonabant 
The present results reproduced the literature findings, as systemic and local 
nicotine administrations induced a rapid increase in extracellular DA in the 
VTA and NAc shell. It is generally accepted that the CB-1 receptor is 
implicated in regulating nicotine’s rewarding effects, as co-administration of 
nicotine with a CB-1 receptor antagonist led to a decrease in nicotine self 
administration, prevents reinstatement to nicotine seeking (de Bruin et al., 
2011; Forget et al., 2009; Shoaib, 2008), and blocked nicotine induced DA 
transients in the NAc shell (Cheer et al., 2007). However in the present 
study the effect of 3 mg/kg nicotine s.c. on NAc shell DA was not blocked 
by co-administration with the CB-1 antagonist rimonabant. Although we 
have no clear explanation for this finding at the present time, it should be 
noted that the dose of 1 mg/kg s.c. tended to inhibit the nicotine-induced DA 
release in the NAc shell (p<0.1).  
 
More convincing results regarding the nicotine-DA-CB-1 interaction were 
obtained when nicotine was administered locally through the microdialysis 
probe. Local infusions of nicotine rapidly increased NAc shell DA levels to 
about 150% of baseline, which is similar to previous reports (Mifsud et al., 
1989; Nisell et al., 1994a, b). The fact that infusing nicotine directly into the 
VTA and the NAc increased NAc shell DA release implies that both regions 
play a direct role in the regulation of nicotine-induced reward. Infusing 
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nicotine into the NAc shell as well as into the VTA increased DA release in 
the NAc shell, again indicating that both regions play a direct role in the 
regulation of nicotine-induced reward (Kleijn et al., 2011b). Interestingly 
the increase in DA release in the VTA as well as in the NAc was dose-
dependently inhibited by systemic administrations of rimonabant. This 
finding suggests that the effects of local nicotine infusions on DA release 
are CB-1 receptor mediated. Although rimonabant was administered 
systemically, and therefore able to bind CB-1 receptors all over the CNS, 
the implicated CB-1 receptors are not necessarily restricted to the VTA or 
NAc shell. This hypothesis is in line with the findings in an experiment in 
which self-administration of ethanol was inhibited by intra-NAc infusion of 
rimonabant (Caille et al., 2007).  
 
The effect of nicotine and rimonabant on endogenous EC levels 
The main finding of the present study was that systemic nicotine not only 
increases extracellular DA levels in the VTA and NAc shell, but also 
increases the levels of ECs in both areas. To the best of our knowledge this 
is the first evidence of nicotine affecting extracellular EC levels in the brain. 
 
While the levels of AEA, OEA, and PEA were significantly increased 
(exceeding 300% of baseline) by nicotine, the levels of 2-AG in the NAc 
increased to 250% of baseline in the NAc shell and only showed a tendency 
towards an increase in the VTA. Since this is the first report presenting 
microdialysis data of effects of nicotine on ECs in the reward pathway, 
direct comparisons with existing data are not possible. However others have 
indirectly investigated the role of these ligands in nicotine induced 
processes. Blocking of the enzymatic hydrolysis of ECs by inhibiting or 
knocking-out fatty-acid-amide-hydrolase (FAAH) has been shown to 
suppress nicotine induced CPP, the development of nicotine self-
administration (Scherma et al., 2008b), and suppresses the reinstatement of 
nicotine seeking (Forget et al., 2009). Inhibition of FAAH by URB597, 
blocked the effect of nicotine on the burst-firing of VTA DA neurons (Melis 
et al., 2008), and inhibits the stimulatory effects nicotine has on NAc shell 
DA levels (Luchicchi et al., 2010; Scherma et al., 2008b). In contrast, 
FAAH knock-out mice and URB597 administration have also showed to 
result in a dose-dependent increase in the rewarding effects of nicotine as 
measured by CPP (Merritt et al., 2008). Interestingly, increasing the dose of 
URB597 in that study actually diminished the increase in rewarding 
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properties of nicotine. This discrepancy indicates the distinct functions of 
the substrates degraded by FAAH. Much of the effects elicited by URB597 
have been ascribed to increased AEA levels. However, a PPAR-α antagonist 
has shown to block the analgesic effects of URB597, suggesting that ligands 
that bind to the PPAR-α receptor, like OEA and PEA, actually mediate these 
URB597 induced effects (Jhaveri et al., 2008). In line with this, it is shown 
that OEA and PEA directly inhibit nicotine reward, by suppressing the 
nicotine induced DAergic effects in the mesolimbic pathway (Melis et al., 
2008). This finding is in line with the negative modulations of reward 
processes induced by URB597 administrations, which suggest that these 
might be OEA and/or PEA mediated. However, the nicotine induced 
increase in OEA and PEA levels in the VTA and NAc in the present study 
are contradictory to the inhibitory effects of these non-CB-1 ECs in 
published data (Jhaveri et al., 2008; Melis et al., 2008). 
 
In the present study nicotine had a stronger stimulatory effect on PEA and 
OEA when compared to AEA and 2-AG. The effect of nicotine on PEA and 
OEA levels shows a gradual pattern reaching high levels more than 60 
minutes post-nicotine administration. The significance of this more 
pronounced increase of OEA and PEA when compared to the CB-1 receptor 
dependent ECs AEA and 2-AG, is presently unknown.  
When specifically looking at AEA and 2-AG, the increase in AEA was more 
pronounced than the effect of nicotine on 2-AG, suggesting that for nicotine 
reward, AEA might be a crucial agonist for the CB-1 receptor. This CB-1 
receptor dependency was expected as AEA was reported to play a critical 
role in mediating the activity of DAergic neurons in the mesolimbic 
pathway after drug administration (Solinas et al., 2006). In addition, it is 
suggested that the by FAAH inhibition enhanced nicotine induced reward 
processes are AEA mediated (Serrano and Parsons, 2011). A differential 
effect on extracellular EC levels regarding AEA and 2-AG levels during 
reward has been noticed before (Caille et al., 2007; Justinova et al., 2005; 
Justinova et al., 2011), and showed extracellular levels of 2-AG and AEA 
that were differentially increased during self-administration of drugs of 
abuse (Caille et al., 2007). Self-administration of ethanol increased 
extracellular NAc shell 2-AG levels, while extracellular AEA levels were 
unaffected. Conversely, self-administration of heroin resulted in a strong 
increase in extracellular AEA levels, while 2-AG only marginally increased. 
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In contrast to the systemic administration experiments direct application of 
nicotine into the VTA (100µM) and NAc shell (1µM) did not modify EC 
levels in the VTA and NAc. A possible explanation for the absence of 
effects of local infusion of nicotine on the ECs is to speculate that CB-1 
pathways located outside the VTA-NAc reward system are involved in the 
CB-1 – nicotine interaction. However this conclusion is at variance with the 
finding that rimonabant blocked the enhanced DA release seen after local 
nicotine infusion (Figures 2 and 3). 
  
 
Effect of rimonabant on the nicotine induced extracellular EC levels 
The current study showed that the nicotine-induced increase of AEA and 
OAE levels in the VTA was CB-1 receptor dependent as rimonabant dose-
dependently antagonized these effects. That the effects of OEA are 
modulated by the CB-1 receptor is an unexpected observation as there are 
no reports mentioning a direct link between this EC and the CB-1 receptor. 
Like other studies have reported rimonabant alone did not affect the release 
of ECs (Caille et al., 2007; Di et al., 2005). This was expected because ECs, 
unlike classical neurotransmitters, are only released upon demand and 
rimonabant acts as an antagonist in the concentrations used in the present 
study. 
This is the first report showing in a single experiment, a direct effect of 
rimonabant on both the rewardive potential of nicotine (increase in NAc 
shell DA) and the ECs AEA and OEA released after systemic nicotine 
administration. From the current results it might be concluded that AEA and 
OEA play a primary role in nicotine induced DA release. Whether this acts 
via a direct (CB-1) or indirect (via PPAR-α on other types of neurons) 
mechanism needs to be determined. 
Earlier studies in which ECs were sampled studied the effects of an 
antagonist not in a single experiment but combined two datasets (Alvarez-
Jaimes et al., 2009; Caille et al., 2007; Giuffrida et al., 1999; Long et al., 
2009; Orio et al., 2009; Villanueva et al., 2009). E.g. in these experiments it 
was shown that EC levels rose during ethanol self administration and that 
rimonabant could reduce this behavior (Alvarez-Jaimes et al., 2009; Caille 
et al., 2007). The technical difficulty of combining their experimental setup 
(behavioral experiment) with microdialysis explains the use of two 
separated experiments. 
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It would be interesting to study the effects of local infusions of both CB-1 
and PPAR-α agonists and antagonists into the VTA while sampling the NAc 
for EC and DA release. These experiments might result in a better 
understanding of the role of AEA and OEA in nicotine induced reward.  
 
To evaluate the role of the CB-1 receptor in the local nicotine infusion 
stimulated accumbal dopamine release, we monitored EC levels during local 
infusions, and monitored the effects of systemic rimonabant on these effects. 
Our experiments showed that the CB-1 receptor dependency of the 
dopaminergic effect after local nicotine infusion was probably not related to 
CB-1 receptors in the VTA or NAc shell since none of the monitored ECs 
was affected by nicotine infusions. Probably CB-1 receptors outside the 
VTA and NAc shell antagonize the effect of local nicotine infusions on 
accumbal dopamine release. 
We noticed an increase in PEA levels in the VTA after rimonabant 
administration (Figures 6 and 7). This increase was blocked during both 
types of nicotine infusions (in the VTA as well as in the NAc). At the 
present time we have no explanation for this effect.  
 
Basal values of EC 
Since sampling ECs is both technically and analytically challenging, there is 
only a limited number of studies available reporting basal EC levels. 
Extracellular levels of EC in the VTA are not published, as are the levels of 
OEA and PEA. However, there are reports of sampling AEA and 2-AG in 
the NAc shell (Alvarez-Jaimes et al., 2009; Caille et al., 2007; Ferrer et al., 
2007; Orio et al., 2009), AEA (corrected for microdialysis recovery) was 
reported to be between 0.56 and 2.8nM, while 2-AG ranged from 4.4 to 
10.3nM. These values are in line with the values found in the present study: 
the level of AEA and 2-AG in the NAc were: 0.53 (corrected for 15% AEA 
dialysis recovery), and 4.95 nM (corrected for 20% 2-AG dialysis recovery). 
These findings support our sampling method, which uses 15 times less β-
cyclodextrine as dialysis-additive. However, the ratio between the level of 
AEA and 2-AG was 9.3, which is higher although not statistically 
significant, than those reported averaging 4.5 (range: 2-7.9). Remarkably, 
the efficiency of sampling was higher for 2-AG that for AEA, in contrast to 
earlier reports (Buczynski and Parsons, 2010). The difference as observed in 
recoveries are probably caused by the type of dialysis membrane used 







The present study shows that nicotine not only enhanced DA release but 
also stimulated the release of all ECs monitored, in both the VTA and NAc 
shell. The finding that systemic nicotine on extracellular levels of AEA and 
PEA was blocked by rimonabant suggests that both the CB-1 and PPAR-α 
receptors are involved in the CB1-nicotine interaction. The results of the 
present study might stimulate future research on the mechanism of nicotine 
reward and the contribution of the mesolimbic reward pathway. Studies 
combining microdialysis and behavioral models might provide more insight 
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This thesis focuses on the reward circuitry localized in the Ventral 
Tegmental Area (VTA) and Nucleus Accumbens (NAc).  In particular the 
role that nicotine and CB-1 receptors play in reward processes related to 
drugs of abuse like nicotine and amphetamine was studied. Although it is 
realized that it was preclinical study, the present results might be useful to 
better understand reward and abuse in humans. 
 
In short 
First the responsiveness of dopamine (DA) release in the reward circuitry 
was re-evaluated, using nicotine as a stimulant (Chapter 2). Next a large 
series of in vitro recovery microdialysis experiments were carried in order to 
identify the optimal conditions for sampling endogenous cannabinoids (ECs) 
(Chapter 5). It is believed that these analytes act as mediators in the reward 
processes underlying addiction. Subsequently, we conducted a study in 
which both the nicotine reward model and the sampling technique were 
combined (Chapter 6). Two further studies during the evolvement of this 
thesis symbolize the versatility of the cannabinoid system in 
neuropharmacology. Chapter 3 describes the effect of amphetamine on DA 
release in four different sub-regions of the reward circuitry, focusing in 
particular at the role that CB-1 receptors play in these processes. In chapter 4 
is it shown that the efficacy of the antidepressant citalopram to enhance 
serotonin release is modulated by CB-1 receptor activity. 
 
More specific 
After a general introduction (Chapter 1), we described in Chapter 2 the 
effect of nicotine in the VTA and NAc shell. The latter brain areas are 
considered crucial in nicotine induced reward processes. E.g. gene knock-out 
experiments have demonstrated the importance of an intact VTA for nicotine 
induced reward processes. In this chapter we studied the effect systemic 
nicotine administration on DA release in the NAc shell, which is regarded as 
being related to reward. Subsquently, local infusions of nicotine were used to 
determine the most sensitive brain regions (VTA or NAc shell) to nicotine. It 
appeared that the NAc shell responded to 1000 times lower nicotine 
concentrations, compared to the VTA. These results were further 
strengthened by electrophysiological experiments showing that only a 
relatively high nicotine concentration of 0.1mg/kg i.v. increased the firing of 
DA cells in the VTA. Apparently the NAc shell is more sensitive than the 
VTA for nicotine to increase the release of DA in the NAc. This indicates 
that not only the VTA is responsible for the nicotine induced reward but 
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rather an interaction between the NAc shell and the VTA. Therefore, the 
NAc might be more than just a signaling center of the VTA, as it might play 
a crucial role in integrating the incoming DA signal into a reward stimulus.  
 
Chapter 3, describes an elaborate microdialysis study, carried out in order to 
identify the brain region(s) responsible for the effects of amphetamine on 
impulsive behavior. Impulsive behavior plays an important role in the 
development and reinstatement of addiction. Microdialysis probes were 
placed in sub-regions of the medial Prefrontal Cortex (mPFC) and the NAc, 
and the monoamines DA, noradrenaline (NE), and serotonin (5-HT) were 
monitored. Systemic amphetamine increased DA and NE levels in both the 
NAc (shell and core) and the mPFC (ventral and dorsal), while 5-HT levels 
remained at baseline. Although the CB-1 receptor antagonist/inverse agonist 
rimonabant alone did not affect monoamine release, it dose-dependently 
inhibited amphetamine-induced DA release specifically in the NAc shell. 
Rimonabant did not affect amphetamine-induced monoamine release in any 
other region. The results in this chapter might therefore provide new insights 
into the pharmacological mechanisms underlying CB-1 receptor involvement 
in amphetamine-induced behavior. Whereas it is likely that the effect of 
rimonabant on amphetamine-induced DA release seen in the NAc shell 
resulted from CB-1 receptor blockade, the region where this effect on DA 
release is initiated remains elusive. Therefore, future research should focus 
on locally inhibiting CB-1 receptor function during an amphetamine 
challenge. It is the author’s hypothesis that the interaction with CB-1 
receptors takes place at GABA receptors in either the NAc shell itself or in 
the VTA. This hypothesis is based on the ability of endocannabinoids to 
inhibit GABAergic activity and by this action indirectly stimulate DA 
release. Further evaluation of the reward processes initiated by amphetamine 
is recommended. Future research should focus on the role of other brain 
areas, including the VTA, in which local infusions of cannabinoids might 
substantiate the postulated hypothesis. Future studies might also validate the 
effect of rimonabant on NAc shell DA release seen after amphetamine 
administration in a behavioral model, preferentially combining microdialysis 
and a cognitive test like the 5-choice serial reaction time test. 
 
Chapter 4 Illustrates the versatility of the CB-1 receptor. The CB-1 receptor 
is the most abundant G-protein coupled receptor in the brain and is localized 
on a variety of neurons (e.g. containing the transmitters GABA, glutamate, 
NE, 5-HT). Therefore, it is to be expected that stimulating or blocking the 
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CB-1 receptor would influence their pharmacological responsiveness. One of 
such interactions is shown in this chapter. Using microdialysis in a brain 
region which is relevant for the clinical effects of the antidepressant 
citalopram, the mPFC, we studied the effect of CB-1 receptor stimulation or 
blockade on the effects of this selective serotonin re-uptake inhibitor (SSRI). 
The results showed that stimulating the CB-1 receptor inhibited the capacity 
of citalopram to increase 5-HT levels, while blocking the CB-1 receptor 
resulted in a prolongation of the effect of citalopram. Since a large 
percentage of depressed individuals use drugs like cannabis, while being 
treated with an SSRI, these results might have implication for the clinical 
efficacy of citalopram. Future research is needed to validate these findings in 
a more chronical SSRI and marijuana use model (both in animals and in 
humans). Moreover, the interaction between the CB-1 receptor on the 
effectiveness of this particular SSRI might be one of many examples in 
which the CB-1 receptor interferes with the pharmacology of CNS drugs. 
Therefore it would be relevant to study the effects of drugs other then 
SSRI’s. Future research might also focus on psychosis, since it is particularly 
this type of mental illness that is often related to marijuana use.  
 
In order to perform the studies described in Chapter 6, a sampling method 
for four different ECs was developed. ECs are lipophilic compounds and 
difficult to handle in microdialysis protocols. Chapter 5 describes the 
conditions that determine the dialysis recovery of the ECs.  β-Cyclodextrine 
proved to be the most effective additive to trap the ECs in the aqueous 
dialysis fluid. Although β-cyclodextrine concentrations up to 30% w/v 
resulted in high recoveries of the ECs, they also increased the fluid recovery 
to levels higher than 100% which would in vivo mean drainage of extra-
cellular fluid from the tissue surrounding the dialysis probe. As an acceptable 
compromise a relatively low concentration of 2% β-cyclodextrine was 
chosen.  
To further understand the underlying mechanism of nicotine-induced reward, 
four different ECs (anandamide (AEA); 2-arachidonoylglycerol (2-AG); 
oleoylethanolamide (OEA); palmitoylethanolamide (PEA)) were studied by 
microdialysis. The ECs were sampled in the NAc shell and VTA, during 
nicotine administration. Simultaneously the nicotine-induced increase of DA 
was determined. The results are described in Chapter 6, in which for the 
first time a sampling method is shown able to sample all four ECs. Systemic 
nicotine administration not only increased the level of DA in the NAc shell 
(as earlier described), but also increased the levels of ECs in the VTA as well 
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as in the NAc. To our knowledge this is the first evidence that nicotine 
administration increases extracellular levels of ECs in the brain.  
As described earlier in Chapter 2, infusion of nicotine directly into the VTA 
or NAc shell increased DA levels in the NAc shell. This increase was 
inhibited by rimonabant, suggesting that the response of DA is CB-1 receptor 
mediated. However, analysis of the EC levels during co-administration of 
rimonabant and nicotine did not further elucidate the underlying mechanism 
of action as nicotine infusion did not modify the ECs in the extracellular 
fluid. Although both systemic and local nicotine administration resulted in a 
(similar) enhancement of DA release in the NAc shell, this was not the case 
with the ECs. Systemic nicotine increased EC levels in the VTA and NAc 
shell. Although local nicotine infusions did increase Accumbal DA levels the 
release of any EC in both the VTA and NAc shell was not. This might imply 
that while nicotine is able to increase EC release in the VTA and NAc, the 
modulating role of CB-1 receptors (shown by the inhibitory effect of 
rimonabant on both EC and DA release) takes place outside the VTA and 
NAc shell. The results described in Chapter 6 highlights some intriguing 
questions. First, which brain area plays the modulating role in EC driven 
nicotine reward? Secondly, why do the levels of ECs increase slower and last 
longer than the more transient increase in DA after the same stimulus? 
 
Options for future studies, that might answer these questions, include the use 
of local infusions of CB-1 receptor agonists and antagonists. In addition, 
infusion of inhibitors of individual EC degrading enzymes (such as FAAH 
and MAGL) into the region of interest might identify the ECs involved. This 
strategy could especially be worthwhile when rapid changes in EC levels that 
do not cope with the time resolution of the microdialysis technique are 





Summarizing the main conclusions of this thesis: 
 
• The Nucleus Accumbens shell region might be more important in 
regulating the nicotine-induced reward processes than previously thought 
 
• The interaction between the amphetamine-induced increase in 
extracellular dopamine and CB-1 receptors is detectable in the Nucleus 
Accumbens shell and not in the Nucleus Accumbens core or the Prefrontal 
Cortex 
 
• Stimulating the CB-1 receptor inhibits the effect of citalopram on 
extracellular levels of serotonin in the Prefrontal Cortex  
 
• Blocking the CB-1 receptor prolongs the effect of citalopram on 
extracellular levels of serotonin in the Prefrontal Cortex  
 
• Adding bovine serum albumin in a concentration of 0.2% is a necessary 
step in preventing endogenous cannabinoids from binding to the inner wall 
of glassware, pipettes and tubing 
 
• Including 2% of β-cyclodextrine in the perfusion fluid of microdialysis is 
an efficient and save way of sampling endogenous cannabinoids 
 
• Nicotine stimulates the release of dopamine and endogenous 
cannabinoids in the Nucleus Accumbens shell and Ventral Tegmental Area. 
The dopamine response to nicotine appeared to be CB-1 receptor mediated, 





































Het onderzoek gepresenteerd in dit proefschrift richtte zich op het 
beloningscircuit in het centraal zenuwstelsel (CZS), waarvan het 
Ventrale Tegmentale Gebied (VTG) en de Nucleus Accumbens (NAc) 
deel uitmaken. Het primaire doel was om de effecten van farmaca op 
de cannabinoid CB-1 receptor in het beloningscircuit te onderzoeken. 
De meeste aandacht ging daarbij uit naar de effecten van nicotine. 
Hoewel het onderzoek dierexperimenteel van aard was kunnen de 
resultaten het inzicht in de effecten van verslavende middelen bij de 
mens vergroten. 
 
In het kort 
Als eerste is het stimulerende effect van nicotine op de afgifte van de 
neurotransmitter dopamine in het beloningscircuit van de rat met 
behulp van de microdialyse techniek bestudeerd. (Hoofdstuk 2). 
Vervolgens zijn, in een uitgebreid in vitro microdialyse onderzoek, de 
meest optimale condities voor het bemonsteren van endogene 
cannabinoiden (ECs) bepaald (hoofdstuk 5). Volgens een gangbare 
hypothese spelen deze ECs een belangrijke rol bij de 
beloningsprocessen die ten grondslag liggen aan verslaving. Dankzij 
de nieuwe bemonsteringsmethode kon in hoofdstuk 6 de rol van ECs 
in de nicotine-geïnduceerde beloning (DA afgifte) worden 
geëvalueerd.  
Daarnaast zijn er in dit promotieonderzoek studies uitgevoerd om 
meer inzicht te geven in de vele werkingsmechanismen van het 
endogene cannabinoid systeem. Hoofdstuk 3 richtte zich op het effect 
van amfetamine op de afgifte van dopamine in een viertal specifieke 
hersengebieden waarvan wordt aangenomen dat deze betrokken zijn 
bij het beloningscircuit. Hierbij is in het bijzonder gekeken naar de rol 
die CB-1 receptoren spelen. In hoofdstuk 4 kon worden aangetoond 
dat het effect van het antidepressivum citalopram (dat de afgifte van 
serotonine in het CZS verhoogt) wordt geremd door CB-1 receptor 
stimulatie en gestimuleerd door CB-1 receptor blokkade.  
 
In meer detail 
Na de algemene introductie (hoofdstuk 1), beschrijven we in 
hoofdstuk 2 het effect van systemisch en lokaal toegediend nicotine op 
de afgifte van dopamine in de VTG en NAc; aan deze hersengebieden 
wordt immers een cruciale rol toegeschreven in de door nicotine 
geïnduceerde beloningsprocessen. Een aanwijzing hiervoor zijn 
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experimenten waarbij gericht genen zijn uitgeschakeld (“knock-out 
experimenten”) of receptoren worden geblokkeerd met behulp van 
antagonisten. Deze experimenten hadden aangetoond dat een intacte 
en functionerende VTG essentieel is voor de nicotine-geïnduceerde 
beloningsprocessen. In hoofdstuk 2 laten we zien dat nicotine de 
dopamine afgifte in de schil van de NAc stimuleert. De dopamine 
afgifte in dit deel van de NAc staat in verband met beloning. Door 
middel van lokale nicotine infusies, direct in de VTG en de NAc schil, 
werd de gevoeligheid voor nicotine in beide regio’s vergeleken. Het 
bleek dat de NAc schil op een veel (tot 1000 keer) lagere concentratie 
nicotine reageerde dan de VTG. Elektrofysiologische experimenten 
bevestigden deze bevinding: Pas een relatief hoge systemische 
dosering van nicotine (0.1mg/kg i.v.) liet een verhoging zien van de 
vuurfrequentie van dopamine neuronen in de VTG. Deze resultaten 
tonen aan dat niet alleen de VTG belangrijk is voor nicotine- 
geïnduceerde beloningsprocessen maar dat het eerder een samenspel is 
tussen de NAc en de VTG. De NAc is dus mogelijk meer dan alleen 
maar een projectiegebied van de VTG. De NAc zou een bepalende rol 
kunnen spelen in de integratie van de VTG-signalen tijdens een 
belonende stimulus. 
 
Hoofdstuk 3 beschrijft een uitgebreid onderzoek – uitgevoerd met 
behulp van microdialyse - dat gericht was op het identificeren van de 
hersenkern die verantwoordelijk is voor het effect van amfetamine op 
impulsief gedrag. Impulsief gedrag speelt een belangrijke rol bij het 
ontwikkelen en het onderhouden van verslaving en verslavende 
handelingen. Er werden microdialyse-probes geplaatst in de 
subregio’s van de mediale PreFrontale Cortex (mPFC) en de NAc. In 
deze hersengebieden werden de extracellulaire concentraties van de 
monoamines dopamine (DA), noradrenaline (NE), and serotonine (5-
HT) bepaald. Systemisch toegediend amfetamine verhoogde de afgifte 
van DA en NE  in de beide subregio’s van de NAc (schil en kern) en 
in de mPFC (ventraal en dorsaal), maar de 5-HT afgifte werd niet 
beïnvloed. Wanneer er kort voor het toedienen van amfetamine een 
CB-1 antagonist werd gegeven, werd de DA-stijging in de NAc schil 
dosisafhankelijk geremd: De CB-1 antagonist alleen gaf geen effect 
op de afgifte van DA te zien. Deze resultaten kunnen mogelijk leiden 
tot nieuwe inzichten in de rol van de CB-1 receptor met betrekking tot 
amfetamine-geïnduceerd impulsief gedrag. Het is echter niet 
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uitgesloten, dat het effect van CB-1 receptorblokkade op het 
amfetamine-geïnduceerde effect heeft plaats gevonden buiten de NAc 
schil, aangezien dit hersengebied signalen van vele andere kernen kan 
ontvangen, waaronder de VTG. Toekomstig onderzoek zal zich 
moeten richten op het locaal blokkeren van de CB-1 receptor in de 
hersengebieden, die in direct contact staan met de NAc schil, tijdens 
een amfetamine toediening. Onze hypothese is, dat de interactie met 
de CB-1 receptoren plaatsvindt in combinatie met remming van 
GABAerge activiteit, in de NAc schil zelf of in de VTG. Deze 
hypothese is gebaseerd op de in de literatuur beschreven waarneming 
dat ECs de door GABA afgifte geïnduceerde effecten kunnen 
remmen, waardoor ze indirect DA afgifte zouden kunnen stimuleren. 
 
Hoofdstuk 4 illustreert de functionele veelzijdigheid van de CB-1 
receptor. Omdat de CB-1 receptor de meest voorkomende G-eiwit 
gekoppelde receptor is in het CZS, en aanwezig is in een grote 
variëteit aan neuronen (GABA, glutamaat, NE, 5-HT, etc.) kan 
verwacht worden dat stimulatie van deze receptor de afgifte van al 
deze neurotransmitters kan moduleren en zo een grote 
verscheidenheid aan processen kan beïnvloeden. Een mooi voorbeeld 
van een dergelijke interactie wordt in hoofdstuk 4 beschreven. 
Met behulp van microdialyse in de mPFC (een gebied dat een 
belangrijke rol speelt in het klinische effect van het antidepressivum 
citalopram) vonden we een sturend effect van de CB-1 receptor op het 
effect van citalopram. Het bleek dat de 5-HT niveaus (veroorzaakt 
door het remmen van de heropname van deze neurotransmitter) 
afnamen, door het stimuleren van de CB-1 receptor met een agonist, 
terwijl blokkeren van de CB-1 receptor met een antagonist het effect 
van citalopram juist kon verlengen.  
Deze modulerende rol van de CB-1 receptor is mogelijk klinisch 
relevant aangezien relatief veel depressieve patiënten drugs zoals 
cannabis gebruiken, terwijl ze onder behandeling staan van een 
selectieve serotonine heropname remmer (SSRI) zoals citalopram. Het 
zou dus mogelijk zijn dat door cannabisgebruik het klinisch effect van 
citalopram wordt verminderd. Toekomstig onderzoek zal zich vooral 
moeten richten op het valideren van deze interactie in een langdurig 
experiment en vervolgens bij de mens. Overigens is de getoonde 
interactie tussen de CB-1 receptor en de SSRI waarschijnlijk slechts 
een  van de (vele?) interacties die een geactiveerde CB-1 receptor kan 
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aangaan. Het zou interessant zijn ook de interactie met andere typen 
antidepressiva te bestuderen, alsmede met antipsychotica, gezien de 
rol die cannabisgebruik speelt bij patiënten met schizofrenie.  
 
Om de rol van de verschillende endogene cannabinoiden in 
beloningsprocessen te kunnen bestuderen is directe bemonstering en 
bepaling van deze lipofiele stoffen een absolute meerwaarde. In 
hoofdstuk 5 worden de condities beschreven die de opbrengst van ECs 
tijdens bemonstering met de microdialyse methode bepalen. Door 
toevoegen van het hydrofiele β-cyclodextrine (een kooiverbinding die 
de ECs kan insluiten) aan de perfusievloeistof, werd de opbrengst (de 
“recovery”) van ECs sterk verhoogd. Hoe hoger de concentratie 
toegevoegd β-cyclodextrine, des te hoger was de opbrengst van ECs. 
Tegelijkertijd werd echter, door een osmotisch effect, een groter 
volume aan perfusievloeistof opgevangen dan er in gepompt werd, 
wat in vivo zou betekenen dat er drainage van de locale extracellulaire 
vloeistof kan optreden. Als acceptabel compromis werd een 
concentratie van 2% β-cyclodextrine gekozen.  
Om het onderliggende beloningsmechanisme van nicotine nader te 
bestuderen, zijn de ECs anandamide (AEA), 2-arachidonoylglycerol 
(2-AG), oleoylethanolamide (OEA) en palmitoylethanolamide (PEA) 
na systemische nicotine-toediening bemonsterd. De ECs werden 
zowel in de NAc schil als in de VTG bepaald, terwijl tegelijkertijd de 
extracellulaire DA stijging werd gemeten. Deze experimenten worden 
in detail besproken in Hoofdstuk 6. In dit hoofdstuk wordt voor het 
eerst getoond, dat met onze methode alle vier ECs met microdialyse 
bemonsterd kan worden. Systemisch toegediende nicotine verhoogde 
niet alleen de DA afgifte in de NAc schil (zoals eerder beschreven), 
maar ook de afgifte van de ECs, zowel in de NAc schil als in de VTG. 
Zover wij weten, is dit het eerste bewijs, dat nicotine in staat is de 
vorming van ECs in het CZS te verhogen. 
Zoals beschreven in hoofdstuk 2, verhoogt directe infusie van nicotine 
in de VTG de DA afgifte in de NAc schil. Deze afgifte werd dosis-
afhankelijk geremd door de (systemisch gegeven) CB-1 receptor 
antagonist rimonabant, wat suggereert, dat deze afgifte CB-1 receptor 
gestuurd is. Echter, analyse van de extracellulaire EC niveaus na een 
locale infusie van nicotine plus rimonabant in de VTG gaf geen 
bevestiging van de mogelijke rol van de CB-1 receptor, want nicotine 
gaf nu geen verandering in de afgifte van ECs. Hoewel zowel 
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systemische als locale toediening van nicotine eenzelfde effect gaf op 
de DA afgifte in de NAc schil, was dit dus niet het geval voor de ECs. 
Dit zou kunnen betekenen, dat hoewel systemisch nicotine de EC 
afgifte in de NAc schil en de VTG verhoogt, het modulerende effect 
van CB-1 receptoren plaatsvindt buiten de NAc schil en de VTG. 
De resultaten van hoofdstuk 6 roepen twee belangrijke vragen op. Ten 
eerste, welk hersengebied speelt de modulerende (hoofd)rol in de EC-
gestuurde nicotinebeloning? En ten tweede, waarom stijgen, na een 
gelijke stimulus, de niveaus van de ECs langzamer en duurt deze 
stijging langer dan de korter durende DA vrijgiftes? 
 
Een eerste optie voor nader onderzoek dat antwoord zou kunnen 
geven op de gestelde vragen, is het locaal infunderen, in relevante 
hersengebieden, van CB-1 receptor agonisten en -antagonisten. 
Daarnaast zou infusie van remmers van onder meer FAAH en MAGL 
(enzymen die ECs kunnen afbreken) in relevante hersengebieden, 
mogelijk de specifieke ECs kunnen identificeren, die betrokken zijn 
bij nicotine-geinduceerde beloning. Deze strategie zou bijzonder 
informatief kunnen zijn, als de veranderingen in EC-niveaus na 
nicotine toediening in feite sneller zijn, dan de in hoofdstuk 6 







Samengevat zijn de belangrijkste conclusies van dit 
proefschrift: 
 
• De nucleus accumbens schil zou belangrijker kunnen zijn in de 
regulatie van nicotine-geïnduceerde beloningsprocessen dan 
voorheen gedacht werd 
 
• De interactie tussen de amfetamine geïnduceerde dopamine 
vrijgifte en CB-1 receptoren vindt plaats in de schil en niet de 
kern van de nucleus accumbens, noch in de prefrontale cortex 
 
• Stimulatie van CB-1 receptoren remt het effect van citalopram 
op de extracellulaire serotonine concentraties in de prefrontale 
cortex 
 
• Blokkeren van CB-1 receptoren verlengt het effect van 
citalopram op de extracellulaire serotonine concentraties in de 
prefrontale cortex 
 
• Toevoegen van bovine serum albumine in een concentratie van 
0.2% is een cruciale stap in het hanteren van endogene 
cannabinoiden omdat het aspecifieke binding aan glas en 
kunststoffen voorkomt 
 
• Het toevoegen van β-cyclodextrine aan de perfusievloeistof is 
een efficiënte en veilige manier om de opbrengst (de 
“recovery”) van de bemonstering van endogene cannabinoiden 
door middel van de microdialyse techniek te verbeteren. 
 
• Nicotine stimuleert de afgifte van dopamine en endogene 
cannabinoiden in de nucleus accumbens schil en het ventrale 
tegmentale gebied. De dopamine reactie op nicotine blijkt 
gemedieerd door de locale CB-1 receptor, terwijl de stijging in 





































As most of the people I would like to thank for their contribution and 
personal help in my thesis mainly speak Dutch I wrote this section 
mostly in Dutch. 
 
Al vroeg in de Master Medisch Farmaceutische Wetenschappen aan 
de RUG kwam ik in aanraking met de afdeling Biomonitoring en 
Sensoring en Brains On-line. Ik wilde daar graag een stage doen met 
microdialyse omdat deze techniek mijn aandacht had getrokken bij 
Solvay. De stage onder begeleiding van Martin en Ben beviel zo goed 
dat ik volmondig “Ja, ik wil” antwoordde op de vraag of ik een 
promotieonderzoek bij hen wilde uitvoeren. Ik heb tijdens mijn vier 
jaar durende onderzoek geen dag gehad dat ik niet met plezier naar het 
werk ging. Dit is voor mij het allerbelangrijkste en zonder de volgende 
mensen zou het ook lang niet zo leuk geweest zijn: 
 
Met bedanken begin ik bij het begin en daarom op de Antonius 
Deusinglaan 1.  
De belangrijkste oorzaak van de plezierige werkomgeving was de 
gezellige groep biotechnici, andere PhD studenten en Post-Docs. 
Karola, Kim, Suzan, Daphne, Annelie, Harm, Azueres en Carlos, 
Wahono, Si, Miranda, Donnatella en Isabella, wat heb ik van jullie 
genoten! Vele practical jokes waren aan de orde van de dag. Helaas 
werkte de helft van de opgezette grappen niet, maar de voorpret was 
voldoende om er weer een week tegen aan te kunnen. Zowel op de 
werkvloer als ernaast hebben we leuke dingen gedaan en zijn vele van 
jullie van collega’s opgewaardeerd naar vrienden. Ik weet zeker dat 
het hier niet ophoudt, al zien we elkaar minder, de volgende afspraak 
is al gemaakt om elkaar weer te zien. Ik heb er zin in. 
Carlos, we had a great time together, both starting to practice judo 
together with our friend and very good scientist to be: Chris. We 
shared laughter, frustration, and dreams on and off the lab. I’m sure 
you will do a good job on finishing your thesis, hang in there! 
Wahono, when you came, you were given a Dutch name: Piet. During 
your PhD period you became more and more Dutch (only the positive 
traits). I’m sure that with your new developed Dutch assertiveness you 
will be able to finish the thesis fast and efficient. Si and Miranda, I 
have enjoyed every bit of your company, advice and trust. I was so 
proud to be your “paranimf”, Miranda, thanks for offering me this 
position!    
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Ik wil Martin, Joost en Gunnar ontzettend bedanken voor de 
ondersteuning die zij mij geboden hebben. Ondanks dat jullie het 
ontzettend druk hadden werd er altijd even tijd vrijgemaakt om mij uit 
te motiveren als het even in de mist liep. Martin, ik heb ontzettend 
veel van je geleerd. Je bent een goede wetenschapper met veel kennis, 
schrijftalent en geduld, waar ik als PhD student dankbaar gebruik van 
heb kunnen maken. Joost, je hebt me ontzettend veel geholpen met de 
papers en morele support wanneer ik die nodig had. Jou 
relativeringsvermogen heeft bij mij veel stress buiten de deur 
gehouden. Ik ben trots jou als een van mijn paranimfen te hebben. 
Gunnar, zonder jou bereidheid mij toegang te geven tot de analyse 
apparatuur (weliswaar in de weekenden) had ik het nooit af gekregen. 
Ik hoop, dat ik je vertrouwen nooit heb beschaamd, want ik realiseer 
me volledig dat dit een unieke situatie was.  
 
Natuurlijk was het allemaal niet zo gestroomlijnd verlopen als ik geen 
administratieve ondersteuning had verkregen van Margriet, Janneke, 
Janine, en Cathy de Haan. Tot op het laatst was ik niet op de hoogte 
van alle procedures en dat heeft jullie veel extra werk bezorgd. Ik heb 
er veel van geleerd en tracht ook bij mijn nieuwe werkgever meer 
energie te steken in procedurele taken. Bedankt voor jullie geduld en 
gezelligheid. 
Ik deelde de kantoorruimte met een paar collega’s van de vakgroep 
Farmacochemie. Hier kreeg ik te maken met Ulrike, Jeroen en Andre. 
Ulrike, ik heb je altijd bewonderd om je werklust en professionaliteit. 
Er zijn maar weinig PhD studenten die zo hard hebben gewerkt om 
hun proefschrift af te ronden. Je doet goed werk bij BOL, ga zo door. 
Jeroen, je optimisme en drive zijn erg aanstekelijk. Andre, jij hebt mij 
echt ondersteund, we kennen elkaar al vanaf onze eerste studie in 
Leeuwarden. Toen ik nog in mijn eentje was op het lab na het 
verhuizen van BOL heb ik erg veel aan je steun gehad. We hebben 
veel plezier gehad en ondanks je pogingen heb ik toch nog bijzonder 
weinig farmacochemische kennis opgenomen. Bedankt voor alles en 
ik ben blij dat je mijn paranimf en vriend bent. 
 
De eerste chromatogrammen die ik heb gegenereerd op het lab waren 
samen met Jan de Vries, de trouwe analist van Ben. Het speelse 
gemak waar jij de HPLC mee aan de praat kreeg als ik weer voor een 
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storing had gezorgd, was wonderbaarlijk. Marius heeft mij ook 
ontzettend veel geleerd met en over de HPLC; het was leuk jullie twee 
verschillende leerscholen te ervaren. Als de ene oplossing niet werkte, 
dan deed de andere dat wel.  
 
Op een gegeven moment kreeg ik de mogelijkheid over te gaan op de 
LC-MS/MS om zo sneller en meer data te kunnen genereren. Dit was 
nooit gelukt als Corry niet het geduld en vertrouwen had, dat ze mij 
gegeven heeft. Wat een topper ben jij toch. De manier van lesgeven is 
wel zo direct, dat het af en toe erg zweten was, maar daardoor was het 
zeer effectief. Ik heb veel respect voor jou en hoe jij het analytisch lab 
hebt omgetoverd van een universitair bij elkaar geraapte inboedel tot 
een volledig efficiënt industrieel lab. Bedankt Corry. Ook wil ik Theo, 
Nynke, Robert, Wim, Daniel, Julien, Saskia, Elvira en Tietie ook 
bedanken voor hun gezelligheid en hulp.  
 
Ik ben Brains-Online (BOL) en haar werknemers erg dankbaar voor 
de middelen, kennis en infrastructuur, die mijn onderzoek mogelijk 
hebben gemaakt. Zonder jullie analysemethoden was het werk een 
stuk trager verlopen en minder interessant geweest.  
 
Voor de productie, levering en ontwikkeling van de probes die ik voor 
mijn onderzoek nodig had kon ik altijd bij de mensen van Brainlink 
terecht. Zonder Korrie, Jeanette en Sylvia was dat nooit gelukt. 
Kirsten wil ik toch wel even extra bedanken. We hebben een hoop 
plezier gehad op onze tripjes naar Neuroscience. Je bent een erg fijne 
collega en vriendin. Bedankt voor het meedenken, het vertrouwen dat 
je me gaf en de fijne samenwerking.  
 
De Neuroscience tripjes waren ook lang niet zo leuk geweest zonder 
de hulp van de slimme accommodatie makelaar en BOL’ler van het 
eerste uur Marieke. Ik heb een hoop van je geleerd met de 
dierregistratie en omgang met de ethische toetsingscommissie. 
I also want to thank Arash, although we did not work together directly 
I have the feeling we would work together very well. Take good care 
of my Dutch friends in the big US of A. 
 
Het laatste jaar zat vol met samenwerkingen die het voordeel van 
werken binnen TIPharma symboliseerden. Zo hebben we in de UvA 
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electrophysiologie met onze glutamaatsensor proberen te combineren. 
Femke, Taco en Wytse bedankt voor jullie inzet en geduld. Helaas 
hebben we het goede resultaat van onze eerste poging niet meer 
kunnen reproduceren, ondanks de inspanningen van Wahono om een 
“royal sensor” in elkaar te zetten. Samen met het VUMC hebben we 
onze velden van expertise ook gedeeld. In een intensief en nachtelijk 
experiment is voor mij uiteindelijk duidelijk geworden dat de 
wetenschap in een universitaire setting niet mijn toekomst is. Toch 
heb ik een hoop positieve ervaringen en elementen uit deze 
samenwerking met Joost, Tommy en Anton gehaald. Joost, ik heb me 
altijd verwonderd over het niveau dat jij al vanaf het begin van je PhD 
traject leek te hebben. Ga zo door, jij kan heel ver komen in de 
wetenschap, succes! Tommy, bedankt dat je wil deelnemen in de 
oppositie tijdens de verdediging van dit proefschrift, een ware eer. 
Ook binnen de RUG hebben we nog een samenwerking opgezet. 
Microdialyse combineren met gedrag. Een uiterst veelbelovende en 
arbeidsintensieve opzet was het gevolg. Romy and Piray, I have 
enjoyed all our quite moments in the lab, you were both very eager to 
learn and taught me a lot as well. I hope that by now both of you are 
(almost) finished. 
Aansluitend wil ik natuurlijk TIPharma bedanken voor het platform 
dat zij bieden voor alle samenwerkingen en de flexibiliteit in richting 
en financiering. 
 
Natuurlijk heb ik het werk niet alleen gedaan. Ik heb een aardige 
groep stagiaires gehad, die voor een deel van het werk 
verantwoordelijk zijn. Ik wil graag Yannick, Mariam, Sibel, Iren, 
Kim, Iris, Jolanda, Angela, Chantal en Balaji bedanken voor hun 
tomeloze inzet. Het begeleiden van jullie was dankbaar werk! Bedankt 
voor jullie inzet en energie en ik wens jullie veel succes in jullie 
verdere carrière. 
 
Catriene, jou wil ik even apart bedanken voor de plezierige 
samenwerking die we gehad hebben. Jou manier van communiceren is 
erg “open” wat een laagdrempelige situatie creëert. Ik heb daar 
dankbaar gebruik van gemaakt in de jaarregistraties voor 
Biomonitoring en Sensoring en bij mijn eigen projecten. Bedankt voor 
de prettige samenwerking! 
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Marianka, ik wil ook jou even bedanken voor de vrijheid die je me gaf 
in het afronden van mijn proefschrift. Ik ben ontzettend blij met de 
functie die ik vervul bij TEVA en het vertrouwen dat jullie vanaf het 
begin in mij getoond hebben. Dank je wel! 
 
Ik wil mijn paranimfen nog even apart bedanken voor de hulp rondom 
het proefschrift en alvast voor de steun tijdens de verdediging ervan. 
Met jullie aan mijn zijde komt het helemaal goed! Bedankt jongens. 
 
Ik wil de leescommissieleden graag bedanken voor de energie die zij 
in het doornemen en goedkeuren van dit proefschrift hebben gestoken. 
Prof. J.M. Koolhaas, Prof. P.G.M. Luiten en A.G.M. van der Zee, 
bedankt!  
 
Hans Zaagsma, ik ken niemand die zo behulpzaam en betrokken is als 
u. Ik ben elke keer weer verrast hoe bevlogen u bent met uw werk. 
Bedankt voor het corrigeren van mijn laatste hoofdstuk en 
samenvatting, dit waren de lastigste en laatste loodjes en natuurlijk 
bedankt voor het deelnemen aan de oppositie.  
 
Mijn officiële begeleiding was in de kundige handen van Thomas en 
Ben. 
Thomas, jij hebt vanaf het begin gefunctioneerd als een voorbeeld. 
Ooit zal ook ik een eigen bedrijf starten. Jij blijft een unieke kerel, zo 
jong en zo gedreven om iets op te zetten wat snelheid, flexibiliteit en 
hoge kwaliteit biedt met een team, dat jij altijd wist te motiveren. Ik 
heb veel van je geleerd. Ik wil nog altijd meer weten. Bedankt. 
Ben, de manier waarop jij mij begeleid hebt, heb ik als bijzonder fijn 
ervaren. Veel vrijheid en verantwoordelijkheid. Je bent een goede 
mentor, wetenschapper in de neurochemie (& archeologie), auteur van 
tekstboeken (& romans) en bovenal een levensgenieter. Bedankt voor 
jouw interesse en geduld in mijn ontwikkeling van wetenschapper en 
mens. Jij bent een echt voorbeeld. 
 
Ik wil mijn vrienden thuis bedanken voor het begrip dat jullie hebben 
gehad voor het feit dat ik minder tijd had door al die weekenden op 
het werk. We hebben des ondanks veel leuke tijden gehad en er gaan 
nog leuke tijden komen, daar ben ik zeker van. Bedankt jongens! 
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Natuurlijk moet ik mijn directe familie ook bedanken voor het begrip 
en de steun die ik van jullie ontvangen heb. Pap en Mam, Arne, Inge, 
Guillaume en Mariet, ik weet nog goed hoe jullie reageerden op mijn 
eerste artikel, ik was zo dankbaar voor jullie reacties. Jullie moeten 
weten, dat ik zonder jullie steun tijdens die periode het praktische deel 
niet binnen de 4 jaar gehaald zou hebben. Inkie, ook bedankt voor de 
creatieve invulling van mijn kaft. Jouw ontwerp maakt het nog 
persoonlijker. 
 
Marjolijne, jij hebt waarschijnlijk het meest moeten inleveren voor 
mijn ambitie. Ik wilde graag promoveren maar zonder jouw steun was 
die investering in tijd en energie zeker niet mogelijk geweest. We 
gaan het qua vakanties snel goed maken. Zonder jouw steun de laatste 
maanden had het afronden van dit proefschrift nog lang op zich 
moeten laten wachten. Als laatste wil ik Nora bedanken. Hoe 
vermoeid of gefrustreerd ik ook thuis kwam omdat experimenten 
mislukten en het schrijven niet vorderde, jij wist mij direct alles te 
doen vergeten met een mooie glimlach. Je hebt inmiddels een zusje 
gekregen: Livia. Ik kan niet wachten om te zien wat jullie met de 
wereld gaat doen. Hij ligt aan jullie voeten! Marjolijne, Nora en Livia, 
bedankt. 
 
 
 
 
 
 
 
  
 
